Production of a camelid antibody in CHO cells and its potential  for the in vitro modification of its N-glycan using N- acetylglucosaminyltransferase III produced in insect cells by Ang, Jann Catherine
  
 
Production of a camelid antibody in CHO cells and its potential  
for the in vitro modification of its N-glycan using N- 
acetylglucosaminyltransferase III produced in insect cells 
 
by: 
 Jann Catherine Ang 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A thesis 
presented to the University of Waterloo 
in fulfillment of the 
requirement for the degree of 
Master of Science 
in 
Chemistry 
 
 
 
 
 
 
Waterloo, Ontario, Canada, 2014 
©Jann Catherine Ang 2014 
  
Author’s Declaration 
 
 
 
I hereby declare that I am the sole author of this thesis. This is a true copy of the thesis, including 
any required final revisions, as accepted by my examiners. 
 
I understand that my thesis may be made electronically available to the public. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii
  
Abstract 
 
 
Monoclonal antibodies have been extensively used for clinical diagnosis over the years. Beyond 
their ability to bind antigens, their ability to invoke or evade immune responses has also led to their 
use in therapeutic applications. These additional characteristics have been linked to the sugar 
molecules naturally attached to the proteins through glycosylation – a post-translational 
modification performed in higher order organisms. Certain N-glycans, glycans attached to protein 
at asparagine residues, have been shown to influence antibody Fc-receptor mediated effector 
functions. Of these, glycans with a bisecting N-acetylglucosamine show promising characteristics. 
The goal of this project is to create a process to remodel a novel therapeutic mAb (EG2 camelid 
antibody against Epidermal Growth Factor Receptor (EGFR)) produced from Chinese Hamster 
Ovary (CHO) cell culture to have a larger fraction of proteins having bisecting N- 
acetylglucosamine. The driving hypothesis is that a robust in vitro process will be better than what 
can be achieved in vivo.  To achieve this goal, expression and purification of truncated N- 
acetylglucosaminyltransferase III (GnT3) using the baculovirus expression vector system (BEVS) 
in the Sf9 insect cell line was used to gain an adequate supply of glycosyltransferase. The truncated 
form of GnT3 contained a C-terminal 6xHistidine-Tag and was cloned downstream of a honeybee 
mellitin (HBM) secretion signal. Activity of the GnT3 produced in insect cells was compared to a 
commercial GnT3 acting on our product of interest and on an IgG glycosylated protein. Active 
GnT3 was utilized to develop a scalable remodeling process to produce bisecting glycan enriched 
antibody pools. 
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Chapter 1: Introduction 
 
 
The use of monoclonal antibodies (mAbs) for therapeutic applications against cancer and 
autoimmune disorders has widely developed in the past 50 years. Whereas the antigen binding 
functionality of antibodies is not affected by post-translational modifications (PTMs), the overall 
effectiveness of a mAb as a therapeutic does indeed hinge on key PTMs. Of these PTMs, 
glycosylation plays a major role. Glycosylation is traditionally an in vivo process that results in the 
addition and modification of sugar moieties on a protein molecule. A specific type of glycosylation, 
N-glycosylation has shown to be vital for the Fc-receptor mediated effector function of antibodies1. 
Although all mAbs produced in culture will have the same specificity for a certain epitope 
 
to which they can bind, these mAbs are not truly identical to each other. This is because the process 
of glycosylation is somewhat stochastic in nature and results in glycoform variants – mAbs with 
different glycan structures attached to them. This means that in a collection of antibodies produced 
in culture, a number of different populations can exist, some having greater potency than others in 
terms of therapeutic effects. To make a more effective therapeutic, a number of initiatives have been 
undertaken to create processes that can produce single-type glycoforms. 
Of all the means possible to alter glycoforms, it is thought that in vitro remodeling may be 
the easiest way to achieve specific glycoforms of interest.  And of the glycoform variants, 
glycoforms having a bisecting N-acetyl glucosamine, are thought to hold significant promise. 
Hodonickzky et al. have previously shown that commercial antibodies such as Rituxan and 
Herceptin can indeed be remodeled from a G0 state using rat N-acetylglucosaminyltransferase III 
(GnT3)2. A number of questions still remain regarding the feasibility of such a process. Can the 
process work with human GnT3 instead of rat GnT3? How accessible is GnT3 (rat or human)? Can
7  
it be produced? Can it be produced in insect cells? What modifications to the GnT3 gene need to 
be made for it to be made for it to be made in insect cells? Can GnT3 work on a novel camelid 
heavy chain antibody? 
Although the primary goal of this project was to produce an active GnT3 using the 
baculovirus expression vector system (BEVS) in Sf9 cell culture to remodel a camelid antibody 
(EG2), it became clear that understanding the substrate, the EG2 antibody, and its initial 
glycopattern was of importance. As such, this thesis explores the production of EG2 in CHO cells 
and the glycopattern of soluble secreted EG2, as well as cell-associated/non-secreted EG2. 
In the second chapter of this thesis, a detailed literature review is given on the protein 
production in Chinese Hamster Ovary cells, and why these cells remain the primary workhorse for 
therapeutic production in industry. This is followed by a detailed look at antibody production in 
CHO cells and notable problems with secretion and aggregation of antibodies. The second half of 
the literature review is dedicated to the baculovirus expression vector system, which serves as the 
platform for the production of the in-house GnT3 used in this work. The baculovirus expression 
vector system (BEVS) consists of a baculovirus vector and an insect cell host; however, for the 
creation of the baculovirus there is a need for genetic manipulation of plasmid DNA, which requires 
the use of a lab strain of Escherichia coli. For this reason, there is a section of the literature review 
dedicated to lab strains of E.coli. A portion of the literature review on BEVS also focuses on the 
limitations of insect cells in terms of their glycosylation ability and some of the current genetic 
improvements that have been made to improve the system. 
Following the literature review, Chapter 3 describes the materials and methods used in this 
work. Specifically, this chapter details the production and purification of EG2 from CHO cells
8  
cultured in shake flasks; the production and purification of GnT3 in a 3L bioreactor; and finally 
the enzymatic transformation of EG2 using GnT3 and UDP-GlcNAc. 
Chapter 4 describes the results of the production of EG2. Eosinophil granule monoclonal 
antibody or also known as EG2 recognizes the epidermal growth factor receptor (EGFR) which is 
strongly expressed on specific cancer cells48. EG2 is a camelid antibody. Usually, camelid 
antibodies originates from the serum of camels, dromedaries and llamas. It is a unique type of 
antibody devoid of light chains. The structure is made of only heavy chains and the antibody only 
has one single domain: the variable domain of the heavy immunoglobulin chain (VHH). Camelid 
antibodies are known to have high thermostability, relatively high proteolytic resistance and high 
expression yields in various expression systems49. 
The EG2 clone is fused with a human constant region structure to make it less immunogenic 
 
and transfected into Chinese hamster ovary (CHO cells)50. There are various mammalian cell lines 
available but CHO cells are often used due to its advantages. CHO cells are the traditional host 
expression system for the pharmaceutical industry since it has a low risk of transmission of human 
viruses since viral entry genes are not expressed in the cells. Also, it has the ability to withstand 
broad changes in pH, temperature, oxygen level and pressure50, 51. Most importantly, CHO cells 
are able to modify therapeutic glycoproteins with human-like glycans through post-translational 
modifications, thus enabling these therapeutic antibodies to be more stable and compatible for 
treatment50, 51.  The degree of glycosylation of EG2 that is found in the CHO cells are mostly the 
sialic acid containing glycans and glycans with glucose moieties attached to mannose-1,3 and -1,6 
alpha branch. 
This chapter also describes the discovery of so-called Russell Bodies in the CHO cells 
studied in this work. The monoclonal antibody, EG2, is produced and secreted.
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 Most proteins in eukaryotes undergo post-translational modifications (PTM) that influence the 
structure and function of proteins. Glycosylation takes place within the endoplasmic reticulum and 
Golgi apparatus of cells and is known to be cell specific54. Monoclonal antibodies contain an N-
glycosylation site on the Fc fragment on both heavy chains. The glycosylation profile of an antibody 
can impact its bioactivity, clinical efficacy, pharmacokinetics, safety and antigenicity55. All secreted 
proteins must undergo a complex pathway before secretion from the cells. Poor protein secretion 
can occur due to improper processing and assembling of the protein56. 
Aggregation of misfolded proteins is likely to occur when the expression of protein is much 
 
greater than the breakdown of misfolded proteins. Protein aggregation is a problem for therapeutic 
antibodies because it reduces their effectiveness, and may affect the quality and safety of the 
product. Aggregation of antibodies can occur at any of the steps throughout production including: 
cell culture, purification, formulation and storage.57 Antibody aggregation during cell culture likely 
affects secretion of antibody and impacts the quantity of antibody produced58. Molecular 
chaperones and folding catalysts are involved in ensuring proteins are properly folded59. Stress in 
the endoplasmic reticulum (ER) may impact the performance of these catalysts or chaperones and 
result in misfolded proteins leading to aggregation.  Misfolding may also be due to over 
accumulation of polypeptides in the ER, called unfolded protein response (UPR) 60. 
Visual inspection of the cells showed signs of aggregation of proteins that are suspected to 
be EG2. Further analysis is discussed in detail in this chapter.  
Chapter 5 describes the production and purification of GnT3. GnT3 catalyzes the addition 
of N-acetylglucosamine (GlcNAc) to the core mannose that will produce a bisecting GlcNAc. This 
enzyme is produced in insect cells, specifically Sf9 cells, which are more cost effective. Once the 
enzyme was produced, it was purified using a His-tag high affinity column. Once the activity of 
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the enzyme was verified, the active GnT3 was used to catalyze the in vitro modification of EG2 
antibody.  
In order for the GnT3 to be properly secreted, the construct was designed to contain a HBM 
tag which is a secretion tag. The activity of the GnT3 is measured using a non-radioactive assay. 
In looking at the activity of this enzyme, two factors involving the donor and acceptor substrates 
were investigated. The donor substrate that is used is UDP-GlcNAc while the acceptor substrate is 
the EG2 monoclonal antibody. The assay involves the use of a coupling phosphatase which 
liberates a free phosphate from nucleotides generated from the glycosyltransferase reaction. 
The free phosphate levels are assessed using a malachite green phosphate detection reagent. The 
concentration of released phosphate is directly proportional to the number of sugar molecules 
transferred. Other factors examined include reaction times, concentration of the acceptor substrate, 
and a comparison of different sources of GnT3. 
Lastly, Chapter 6 discussed the problems and opportunities with the use of insect cell derived 
human GnT3 for the remodeling of antibodies, and presents what can be concluded from this work 
and identifies new questions that have arisen as a result of this work. 
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Chapter 2: Literature Review 
2.0 Expression Systems 
2.1 Mammalian Cells 
2.1.1    Chinese Hamster Ovary Cells 
 
Chinese hamster ovary (CHO) cells are the most widely used cell line for commercial protein 
production. Some of the most prominent qualities of this cell line include: the inability to propagate 
human pathogenic viruses, the ease in which foreign DNA is transferred into its genome and their 
rapid and robust growth1. CHO cells encompass a large number of very different cell lines. Industrial 
CHO lines include those having a dihydrofolate reductase (DHFR) gene mutation – a defect that 
facilitates the introduction of transgenes with a functional copy of DHFR, which then acts as a 
selectable marker21. 
The specific cell line used in this thesis is the CHO DUKX cell line, which contains a 
deletion of one DHFR allele and an inactivating mutation in the second allele22. A stable cell line is 
generated through the integration of exogenous DNA containing the gene of interest into a 
transcriptionally active site of host genome22. Due to cost, another way to develop a stable cell line is 
through the delivery of a plasmid DNA containing the gene of interest into host cells capable of 
exponential growth. The common biophysical methods or chemical agents that are used include: 
electroporation, cationic lipids, polycations, and calcium phosphate22. 
2.2 Antibodies 
 
 Immunoglobulins are glycoproteins that are produced by plasma cells in response to the 
presence of antigens.   The two main functions of immunoglobulins (Ig) are antigen binding and 
effector function stimulation. The basic structure of an IgG monomer consists of one or more units, 
each containing four polypeptide chains: two identical heavy chains (H) and two identical light 
chains (L). Beyond consisting of light and heavy chains, antibodies can be described as having 
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antigen binding fragment and a crystallizable fragment. Antibodies can also be described by their 
variable and constant regions. Constant region is the part of the light or heavy chain of antibody with 
a free carboxyl group end. The constant region has similar amino acid sequence from one antibody 
to another. Whereas, variable region differs in all antibodies produced by a single B cell or B cell 
clone. The variable (V) regions are found at the terminal ends of the polypeptide chains and shows 
variation in amino acid composition compared to the constant (C) regions1  (Figure 2.1). Each L 
chain consists of one variable domain and one constant domain, whereas, the heavy chain consists 
of a variable domain and three constant domains. A bilaterally symmetric structure consisting of a 
combination of noncovalent interactions and covalent disulfide bonds hold the light and heavy 
chains together7. Another feature of an antibody is a paratope, it is a small region on the Fv region 
(variable domain) that recognizes an epitope on a specific antigen during the antigen binding 
mechanism. 
Immunoglobulins can be digested with a proteolytic enzyme called papain, which cleaves 
the Ig at the hinge region on the H-H inter-chain disulfide bonds. The treatment results in three 
fragments of approximately identical sizes.   Two of the fragments are called fragment antigen 
binding (Fab) since they contain the antigen binding sites of the antibody. The VH and VL regions 
create the combining site, portion of the antibody that makes a physical contact with corresponding 
antigen, of the antibody that allows the antibody to bind to a specific epitope. Different 
combinations of VH and VL result in a variation of antibodies that can bind to a specific epitope. 
The third fragment that is produced is the fragment crystallizable region (Fc region). The Fc region 
contains the remainder of the two heavy chains, where each heavy chain fragment is comprised of 
CH2 and CH3. The effector function of IgGs is mediated by this Fc region by means of binding to 
complement proteins such as C1q and cell surface receptors (Fc receptors, Fc gamma RI, II and II) 
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Figure 2.1: Schematic picture of an IgG antibody. Immunoglobulins consist of four polypeptide 
chains: two heavy chains, represented in blue, and two light chains, represented in orange. Each 
light and heavy chain consists of variable and constant regions that are represented by a lighter 
shade and a darker shade, respectively. The Complementarity determining regions (CDRs), which 
determine the protein’s affinity and specificity for specific antigens, are represented by brown 
strips. Lastly, the antibody-binding site is circled in red. 
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There are five primary classes of immunoglobulins: IgG, IgM, IgA, IgD and IgE. These 
classes are differentiated by the molecular differences in their respective heavy chains.  IgG is the 
most common Ig antibody present in humans and consists of gamma-chains that are used for 
secondary immune responses to an antigen23. IgG is the main antibody used in therapeutics and 
immunological research. 
2.3 Polyclonal vs. Monoclonal Antibodies 
 
To use antibodies for immunoassays, antibodies can be produced as either polyclonal or monoclonal 
antibodies. Polyclonal antibodies are produced by different B-lymphocytes in response to an antigen 
injected into a live animal. The heterogeneous mixture containing the polyclonal antibodies 
recognizes different epitopes on the same antigen (Figure 2.2) 23. Polyclonal antibodies are purified 
from the serum of immunized animals such as mice, rabbits, goats or horses. The serum contains a 
diverse pool of antigen-binding immunoglobulins of several different classes and subclasses23. 
The main disadvantage of polyclonal antibodies production is that some antibodies generated are 
non-specific. In immunoassays, this lack of specificity causes a decrease in accuracy and an increase 
in background noise24. Furthermore, every batch of polyclonal antibodies produced can vary, 
resulting in problems of consistency24. 
In contrast, monoclonal antibodies (mAbs) bind to one specific epitope on an antigen. 
Monoclonal antibodies are purified from an individual B-lymphocyte providing a source of 
homogeneous antibody binding to a specific epitope on an antigen 25.  The major disadvantage of 
monoclonal antibodies is that the B-lymphocytes must be isolated from spleen or lymph node cells. 
B-lymphocytes, however, have short life spans and are not able to be cultured directly to produce 
useful amounts of antibodies25. Fortunately, the development of mouse hybridoma cells by Kohler 
and Milstein overcame these drawbacks24, 25. Ever since, the field of protein therapeutics has
15  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Production of Polyclonal Antibodies. The animal, a rabbit in this case, is injected with 
an antigen that will generate B-cell clones that produces antibodies with multiple epitopes41 
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expanded significantly, with the ability to produce antibodies in a variety of cell lines, including 
the most industrially used Chinese Hamster Ovary (CHO) cells. 
2.3.2 Camelid Antibodies 
 
 
Camelid antibodies are derived from Bactrian camels, dromedaries and llamas. They are different 
from a conventional antibody consisting only of heavy chains. The single N-terminal domain of 
camelid antibodies bind antigen without domain pairing, combination of heavy and light chains of 
antibodies26. Furthermore, these heavy-chain antibodies lack the CH1 domain that interacts with 
the light chains. Camelid are unique due to their single N-terminal domain also known as VHH 
domain which are also referred to as a Nanobody. As shown on Figure 2.3, these heavy-chain 
antibodies do have VHH domains. The VHH domains contain four framework regions (FR) that form 
the core structure of the immunoglobulin domain and three complementarity-determining regions 
(CDR), which are important in antigen binding. An interesting feature of the VHH region is the 
presence of amino acid substitutions at four FR2 (positions 37, 44, 45 and 47) positions that are also 
conserved in conventional VH domains26. The advantages of a camelid single-domain antibody 
include their high solubility, high physiochemical stability, rapid tissue penetration and fast 
clearance making them appealing for therapeutic applications26. 
2.4 Beyond Antigen Binding 
 
Beyond antigen binding, antibodies are recognized by the immune system. Binding of antibody to a 
specific target cell can induce apoptosis, agglutination and precipitation of the antigen-antibody 
complex. The precipitation is eliminated by phagocytosis or by immunogenic responses such as 
antibody-dependent cell cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) 23. 
ADCC involves natural killer (NK) cells that have receptors on the surface to bind to the Fc portion 
of certain subclasses of IgG. Once the NK cells are bound to the Fc region, it releases perforins, 
proteolytic enzymes (granzymes) and chemokines that will lead to apoptosis of the targeted cell8.
17  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Schematic diagram of conventional (a) and heavychain (b) antibodies and 
fragments thereof. Variable domains derived from the antibody heavy (VH) and light (VL) 
chains are shaded dark gray and light gray, respectively, whereas constant domains (CH and CL) 
are not shaded. Note the absence of the light chain and CH1 domain in heavy-chain antibodies. 
Antibody domains that pair by noncovalent interactions are indicated by overlaying them. The 
VHH domains contain four framework regions (FR) that form the core structure of the 
immunoglobulin domain and three complementarity-determining regions (CDR), which are 
important in antigen binding. 
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On the other hand, CDC uses the complement cascade to mediate the lysis of cells by utilization 
of the C1q component of the complement cascade2, 23. 
Due to the importance of antibodies in the immune system, they are greatly used as 
alternative therapies to treat diseases. Monoclonal antibodies from murine hybridomas were once 
used as an initial step in treatment regiments to cure various diseases. For example when organ 
transplantation is needed, early hybridoma antibodies elicited severe immune responses that caused 
patients to reject their transplants. Therefore, surface molecules on cells crucial for allograft rejection 
was identified and mAb-based therapy was used in preventing the rejection.   In 1986, Ortho Biotech 
introduced a chimeric antibody, called Muromonab-CD3 (Orthoclone OKT3), to inhibit transplant 
organ rejection.  Muromonab-CD3 combined a human Fc region with a murine Fab fragments, 
retaining the antibody’s specificity without triggering an adverse immune response. The development 
of chimeric antibodies significantly advanced success of antibodies as therapeutic agents. Antibody 
products such as Avastin, Herceptin, Humira, Rituxan and Xolar are all humanized antibodies and 
are currently amongst the leading therapeutics on the market against certain cancers and autoimmune 
diseases25. 
2.5 Baculovirus Expression System 
 
 
Baculoviruses are a diverse group of occluded viruses found mostly in insects. This large family 
of occluded viruses are composed of two genera which are differentiated by the size of their 
occlusion bodies. Nuclear polyhedrosis viruses (NPVs) produce large polyhedron-shaped structures 
called polyhedral which contain many virions. In contrast, granulosis viruses (GVs) have smaller 
occlusion bodies called granules, which normally contain a single virion3. Common to both is the 
structure of the virion. They are usually 40-50 nm in diameter and 200 – 400 nm in length3. The 
virion is composed of a viral nucleocapsid: a 130 Kbp double-stranded circular DNA condensed into 
a nucleoprotein structure surrounded by the capsid. 
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As part of the Baculovirus Expression System these viruses are genetically modified to carry 
foreign genes that are introduced into a region of the viral genome that is nonessential for virus 
replication through homologous recombination using a transfer vector. 
The Baculovirus Expression Vector (BEV) system is commonly used for production of 
proteins because of its various advantages. This system is capable of producing very high levels of 
recombinant proteins. When a virus infects insect cells, up to 50% of the total cellular protein that is 
produced can be the protein of interest4. In addition, the proteins that are produced using the BEV 
system are biologically active since they end up having post-translational modifications similar to 
those present in the native form of the protein5. 
The foreign genes are usually controlled by polyhedron and p10 promoters. The baculovirus 
that are commonly used for the expression of recombinant proteins are the Autographa californica 
nuclear polyhedrosis virus (AcMNPV) and the Bombyx mori nuclear polyhedrosis virus (BmNPV). 
Both viruses have genomes of approximately 130 kbp6. 
2.6 Insect Cells 
 
The very first insect cell line was established from ovarian tissue of Antheraea eucalypti, which 
was grown in medium that contained silkworm (Bombyx mori) plasma 7. The two most common 
insect cell lines are derived from the immature ovaries of Spodoptera frugiperda pupae (Sf9 and 
Sf21)8. 
2.6.1 Spodoptera frugiperda cells 
2.6.1.1 IPLB-SF-21 
 
The Sf21 cell line was cloned from pupal ovarian tissue of the Fall Army Worm Spodoptera 
frugiperda. This cell line was developed by Vaughn et al. with hemolymph-supplemented medium. 
The population doubling time of this cell line is approximately 26 to 30 hours8. The Sf21 cell line
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supports replication of the Autographa californica nuclear polyhedrosis virus and the S. frugiperda 
nuclear polyhedrosis virus8. 
2.6.1.2 Sf9 Cells 
 
As described by Smith and Summers in 19876, Sf9 is a subclone of IPLB-SF-21. The IPLB-SF-21 
cell line was observed to support the replication of the Autographa californica nuclear polyhedrosis 
virus8. Sf9 consists of different key features like Sf21 such as the cells can grow either adherent or in 
suspension, and can be adapted to serum free medium. Compared to mammalian cells, a CO2 
incubator is not needed to grow these cultures since the media is buffered with phosphate rather 
than carbonate. Notably this cell line can also be grown in a carbonate buffer. Also, these cells have 
an optimal temperature of 27-28°C rather than 37°C9. 
2.6.1.3 Trichoplusia ni (High Five) 
 
This cell line is derived from the eggs of the cabbage looper and was established in serum free 
medium. High five cells are susceptible to two distinct baculoviruses and are highly productive in 
serum-containing and serum-free medium compared to the other insect cell lines10. Compared to Sf9 
and Sf21 cell lines, Trichoplusia ni which infected with vectors expressing the same genes (LacZ 
and SEAP gene) showed higher levels of both ß-galactosidase and secreted alkaline phosphatase per 
cell11. 
2.6.1.4 SfSWT6 Cells 
 
One of the major limitations for production of proteins in insect cells is the production of 
therapeutic proteins lacking complex type N-glycans, which in turn reduces their efficacy12. 
Specifically, the N-glycans found on insect cell produced proteins are mainly of a high mannose 
type or non-fucosylated and core-fucosylated tri-mannose structures13 (Figure 2.4). To overcome 
these limitations, the N-glycan processing pathway in insect cells has been extended through the 
co-infection of Sf9 cells with recombinant baculoviruses that encode mammalian 
21  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Comparison of IgG1 N-glycan structures expressed in CHO, Sf9, “High Five” and 
Mimic Sf9 cell lines. There are different N-glycan structures that are present in the different cell 
lines. It was observed that more complex N-glycan structures are found in CHO cells compared to 
the other cell lines. (a) The CHO population majorly consists of fucosylated biantennary N-glycan 
structures with two terminal N-acetylglucosamine residues. (b) Whereas, the IgG1 purified from 
Sf9 cells primarily consists of smaller biantennary structures which has no terminal galactose 
residues. (c) Comparable to the structures found in Sf9 IgG1, “High Five” cells carries two fucose 
residues. (d) The structures identified in analysis of N-glycans from IgG1 expressed in Mimic Sf9 
cells, closely resemble the ones found in IgG1 expressed in CHO cells. Nevertheless, the amount 
of galactosylated IgG1 in Mimic Sf9 cells is considerably lower than in CHO cells. 
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glycosyltransferase genes, enabling the production of proteins carrying glycans that are structurally 
identical that can complex N-glycans produced by mammalian cells14. 
SweetBac has the capability for N-linked glycosylation modifications. It was constructed 
using a glycol-module that consists of open reading frames coding for C. elegans GnTII and a 
bovine GalT controlled by p10 and polyhedron (polh) promoter, respectively, which was integrated 
into the loxP site of a MultiBac genome12 (Figure 2.5). The functionality of this system was tested 
through the introduction of heavy and light chain open reading frames of the human HIV anti-gp41 
antibody 3D612. 
Sf9 and High Five cells lack cytosine-5’-monophospho (CMP)-sialic acid which is known 
to be required as a donor substrate for glycoprotein sialylation. It was discovered that these insect 
cells has an endogenous sialic acid salvaging pathway which produces and imports CMP-sialic acid 
that is utilized by mammalian sialytransferases which supports recombinant glycoprotein 
sialylation15. Therefore, in developing genetically modified insect cell lines to express mammalian 
proteins, Spodoptera frugiperda (Sf9) was transformed with six mammalian genes, which resulted 
in the generation of the SfSWT-4 cell line that is able to produce sialylated glycoproteins when 
cultured with the sialic acid precursor. SfSWT-6 was obtained by SfSWT-4 transforms with a human 
CMP- sialic acid transporter (hCSAT) gene. The new daughter cell line showed higher levels of cell 
surface sialylation and recombinant glycoprotein sialylation15. 
2.7 Bacteria 
 
 
Escherichia coli (E .coli) cells are gram-negative, anaerobic, rod-shaped bacteria that are commonly 
found in the lower intestine of warm-blooded organisms. This bacterium is the most widely studied 
prokaryotic model organism and serves as the host organism for the majority of the work performed 
using recombinant DNA. This is due to E. coli’s ability to be grown easily under
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Figure 2 . 5:   Schematic representation of SweetBac.   A glycomodule that consists of the open 
reading frames of C. elegans N-acetylglucosaminyltransferase II (GnTII) and bovine B4- galactosyl-
transferase I (GalT) was integrated in the loxP site of the MultiBac genome. The generated viral 
backbone was used for the expression of 3D6 antibody heavy (HC) and light (LC) chain genes by 
integration in the standard Tn7 site. The vector which consists the HC and LC genes, consists of 
different features such as kanamycin resistant gene and ori site. Whereas, the MultiBac genome has 
double antibody selection gene which are Ampicillin and Kanamycin. This will ensure of the 
expression of only the protein of interest. Adapted from: Palmberger, D. et.al. (2012). SweetBac: A 
New Approach for the production of mammalian glycoproteins in insect cells. PLoS ONE, 7(8). 
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conditions where it takes approximately 20 minutes to reproduce.  E .coli has various strains and 
the specific strain that was used in this work was DH10Bac. 
2.7.1 DH10Bac 
 
The DH10Bac is an E .coli strain which was engineered to generate baculovirus vectors in insect 
cells.  This cell line contains a parent bacmid, bMON14272, and a helper plasmid, pMON7124. The 
parent bacmid contains the mini-F replicon, the kanamycin resistance gene, the attTn7 site and the 
lacZα complementation factor. The helper plasmid contains the tnsABCD regions that supplies the 
transposition proteins required for insertion of the mini-Tn7 from the donor plasmid, which contains 
the gene of interest into its target site on the parent bacmid. The shuttle vectors are constructed by 
the transposition of the mini-Tn7 from the donor plasmid to the attachment site on the parent shuttle 
vector in trans by the helper plasmid. The mini-Tn7 consists of the expression cassette that has a 
gentamicin resistance gene, a baculovirus promoter, a foreign gene and an SV40 poly (A) signal 
inserted between the left and right arms of Tn7. This cell line is resistant to the effects of ligase and 
ligase buffer allowing it to tolerate the addition of small amounts of undiluted ligation reactions. 
Furthermore, its genotype consists of φ80dlacZDM15, which provides an alpha- complementation of 
the B-galactosidase gene from the bacmid vector. 
2.8 Glycosylation 
 
The majority of proteins produced in eukaryotes undergo some type of post-translational 
modification (PTM) that influences the structure and function of the specific protein27. One of the 
most common PTM is glycosylation. Glycosylation takes place in the endoplasmic reticulum (ER) 
and the Golgi apparatus. It is known to be species- and cell-specific therefore the glycosylation of 
each  protein  is  dependent  on  the cell  or  tissue in  which  it  is  produced27.  Glycosylation  is 
differentiated into two groups: N-linked and O-linked, depending on the glycan-peptide linkage 
regions28 (Figure 2.6). 
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Figure 2.6: Various Glycosidic Linkages. N-linked glycosylation is a glycan that binds to 
the amino group of asparagine in the ER. While O-linked glycosylation are monosaccharides 
which bind to the hydroxyl group of serine or threonine in the ER, Golgi, Cytosol and nucleus. 
Reference: ThermoScientific (2013). Protein Glycosylation. Adapted from: Rudd P. M. and 
Dwek R. A. (1997) Glycosylation: Heterogeneity and the 3D structure of proteins. Crit Rev 
Biochem Mol Biol. 32, 1-100. 
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N-glycans are linked to asparagine (Asn) whereas O-glycans are linked to serine (Ser) or 
threonine (Thr) residues. More specifically, N-glycans have a reducing terminal N- 
acetylglucosamine attached to the amide group of Asn through an aspartylglycosylamine linkage29. 
All N-glycans are produced through the same common pathway, which starts in the ER with the 
transfer of a preformed oligosaccharide to an Asn residue. The Asn residue is typically found as 
part of an Asn-X-Ser/Thr sequence, where X is any amino acid except for proline30. There are three 
classes of N-glycans: High-mannose, Hybrid and Complex. High-mannose N-glycans contain 
several highly branched mannose residues on both branches of the glycans forming a simple 
structure (Figure 2.7). Hybrid glycans consist of a single complex high-mannose branch. Complex 
glycans are the most frequent glycans found in mammalians and can be bi-, tri- or tetra-antennary. 
The structure of the complex type glycan can have a bisecting N-acetylglucosamine (GlcNAc), a 
core-fucose or terminal sialyation28. In contrast, O-glycans are extremely diverse in nature. For O- 
glycans, N-acetylgalactosamine (GalNAc) is attached to the hydroxyl groups of Ser or Thr residues 
within the polypeptide31 
2.9 N-glycosylation 
 
N-glycosylation occurs co-translationally where the glycan is attached to the forming protein as it 
goes through the ER pathway29. This type of glycosylation starts by the assembly of a precursor 
glycan, then the attachment of the precursor glycan to the protein, followed by trimming and 
maturation of the glycan as it passes through the various organelles containing the necessary 
enzymes for the process32. An enzyme called oligosaccharide transferase (OSTase) then scans the 
nascent polypeptide for the conserved sequence Asn-X-Ser/Thr and attaches the precursor glycan 
at that site30. 
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Figure 2.7: Three major type of N-glycans. High mannose glycans contain unsubstituted terminal 
mannose sugars which typically contain between five and nine mannose residues attached to the 
GlcNAc core. Whereas, Hybrid glycans contains both unsubstituted terminal mannose residues and 
substituted mannose residues with an N-acetylglucosamine linkage. Lastly, Complex has GlcNAc 
residues at both the alpha-3 and alpha-6 mannose sites. Made using Glycowork Bench 2. 
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2.10 Glycosyltransferases 
 
Glycosyltransferases are enzymes involved in glycan biosynthesis; they typically add one 
monosaccharide at a time to specific positions on specific glycan precursors31. These enzymes found 
within the ER-Golgi pathway catalyze reactions involving the transfer of monosaccharide 
components from high-energy nucleotide sugar donors to the glycan3. A specific glycosyltranferase 
that modifies glycans includes the B-1,4-galactosyltransferase 1, an enzyme found in the golgi that is 
responsible for the galactosylation of both glycoproteins and glycolipids. Another enzyme is N- 
acetylglycosaminyltransferase I (GnT I), also found in the Golgi that transfers GlcNAc residue to 
oligomannose core structures and results in hybrid and complex N- linked oligosaccharides33. Gnt- V 
catalyzes the attachment of a B1-6 GlcNAc residue which results in branched N-glycans34. 
Subsequently, N-linked oligosaccharides can be further modified by N- 
acetylglucosaminyltransferase III. 
2.10.1 N-acetylglucosaminyltransferase III (GnT3) and bisecting GlcNAc 
 
β-1,4 N-acetylglucosaminyltransferase III (GnT3) catalyzes the addition of N-acetylglucosamine in 
β-1-4 linkage to the B-linked mannose in the core regions of N-glycans to form a bisecting GlcNAc 
(Figure 2.8)35. GnT3 is a type II membrane glycoprotein composed of 536 amino acids and its size 
is about 60 kDa35. The domain structure is composed of a short amino terminal cytoplasmic tail, 
transmembrane and neck regions and a long carboxyl terminal catalytic domain projecting into the 
Golgi lumen (Figure 2.9)36. The catalytic domain has three potential N-glycosylation sites at 
Asn243, Asn261 and Asn39936. Previous research has suggested that the activity of GnT3 is 
regulated by post-translational modification such as phosphorylation and glycosylation36. The 
importance of these post-translational modifications have been investigated by inhibiting 
glycosylation and phosphorylation modification of GnT3. 
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Figure 2.8: Addition of bisecting GlcNAc catalyzed by GnT3. The glycan structures are shown 
in CFG nomenclature. Each symbol represents a certain moiety. The blue square represents Glucose, 
green circle represents Mannose, yellow circle represents Galactose and red triangle represents 
Fructose. The structures were generated using GlycoWorkBench. 
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Figure 2.9: Glycan Assembly and Attachment. The precursor glycan synthesis begins on the 
cytosol of the Endoplasmic Reticulum and is flipped into the ER lumen. OSTase transfers the 
precursor glycan to the Asn residue on the nascent protein. 
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Tunicamycin which blocks the core glycosylation and prevents for the initial step of N-glycan 
processing has been used36. GnT3 catalyzes the transfer of a GlcNAc from UDP-GlcNAc to the core 
β-mannosyl moiety of an N-glycan acceptor37. The addition of the GlcNAc creates a β1-4 linkage 
between the core-mannosyl, which results in a bisecting GlcNac31 (Figure 2.8). The reaction 
catalyzed by GnT3 is inhibited by β1-4-galactosylation of the Man-α1-3 branch. α1-6 core-fucose 
has no effect on GnT3. Interestingly, the presence of a bisecting GlcNAc was seen to increase the 
activity of adenylyl cyclase III, which plays a role in Alzheimer’s disease38. Specifically, it also 
has an effect on integrin mediated cell adhesion and cell signaling. 
2.10.2 Background on GnT3 and its activity 
 
As formerly studied, post-translational modification is an important factor for proteins to properly 
function or secreted to the cytosol. In mammalian cells, there are a wide variety structures of the 
oligosaccharides of glycoproteins and glycoproteins. Due to the findings that these structures change 
during the embryogenesis and cell differentiation shows that the surface oligosaccharides play a 
specific role in cell-cell interaction36,41. Therefore, studies on glycosyltransferases are vital since it 
controls the synthesis of different types of oligosaccharides. The specific glycosyltransferase that is 
studied is the N-acetylglucosaminyltransferase III (GnT3) which acts on the production of a bisecting 
GlcNAc residue in the B-linked mannose of the trimannosyl core of the oligosaccharides. The first 
GnT3 activity that was observed was in hen oviduct and further studies was done and extracted 
from rat kidney and human B lymphocytes36, 41. Therefore, previous studies on GnT3 was done where 
it was sequenced and each domain was identified. 
In this specific study, the human GnT3 will be looked at. Taniguchi et. al have compared the 
predicted amino acid and nucleotide sequences  for both  rat and human Gnt3. When it was 
compared, it was shown that there is 86% homology at the nucleotide coding sequence level, 50% 
at the nucleotide 3’ noncoding sequence level, and 91% at the amino acid sequence level. Both
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amino-terminal transmembrane domain and the catalytic domain are well conserved in the two 
species. The only difference that was identified is that the human GnT3 is a few amino acid shorter 
compared to rat GnT3 since it has four amino acid deletion and difference in the COOH terminal34. 
2.11 Protein Secretion and Aggregation 
 
Protein trafficking in eukaryotes involves the compartmentalization that includes elaborate 
mechanisms in targeting nascent proteins to the correct compartment61. Typically each protein 
has a code within their sequences that are scanned in each stage of their trip to the specific target. 
Depending on the destination of each protein, it is synthesized in a different compartment. Such 
as, proteins that are targeted to the cytosol, mitochondria, peroxisomes or chloroplasts are 
synthesized on free ribosomes whereas proteins that are targeted for secretion, ER, Golgi or 
lysosomes are synthesized on the membrane bound ribosomes of the rough ER. 
Secretory proteins are directed to the ER by a signal sequence that is characteristically a 
stretch of 9 or more hydrophobic residues. This signal sequence is recognized by the signal 
recognition particle (SRP) which initiates the assembly of Sec61 complex. The Sec61 complex 
acts as the translocator to allow passage of the polypeptide chain across the bilayer62. The ER 
signal sequence is cleaved off by a signal peptidase except for the signal sequences that are 
found within the polypeptide instead of the N-terminus which are not cleaved. The orientation of 
the polypeptide depends on the charge distribution on either side of the signal sequence62. The 
folding of the protein is aided by chaperones and protein disulphide isomerase within the ER 
lumen63. 
Most proteins in eukaryotes undergo post-translational modifications (PTM) that influences 
the structure and function of the specific protein (25T). One of the common PTM is glycosylation 
which take place within the endoplasmic reticulum and Golgi apparatus of cells which is species 
and cell specific27.  The more common type of glycosylation is N-linked glycosylation which 
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involves the attachment of precursor oligosaccharide to asparagine residues in the ER. The 
precursor is transferred from a dolichol lipid moiety in the ER membrane by oligosaccharyl 
transferase.  Immediately after the transfer, all three glucose residues and one mannose residue 
are removed. The precursor is further modified in the Golgi to produce the mature glycoprotein by 
trimming certain sugars and addition of others63. 
Improper processing and assembling of the protein leads to poor protein secretion56. Thus, 
misfolded proteins can be a cause of protein aggregation.  Typically, protein aggregation involves 
the formation of insoluble precipitates due to the protein concentrations exceeding the solubility 
limit. There are different types of protein aggregation that are identified as either ordered or 
disordered64. For example, amyloid fibrils which are found both in in vivo and in vitro are 
considered as ordered aggregates whereas inclusion bodies are considered to be in vivo disordered 
aggregates. In particular, protein aggregation was always assumed to form due to misfolding of 
protein. The formation of inclusion bodies are believed to arise from hydrophobic aggregation of 
unfolded or denatured states. Inclusion bodies are common when proteins are overexpressed65. 
The process of aggregation starts off with the intermolecular interaction of the hydrophobic 
surfaces on the structural subunit of one molecular to a matching hydrophobic surface area of a 
neighboring molecule. Initially, when dimer and tetramer aggregates are formed, it remains 
soluble until it reaches a size which exceed the solubility limit. Aggregation often appears to be 
irreversible due to the slow rates of disaggregation65. 
Specific intercellular protein aggregates are called the Russell bodies (RB), condensed 
immunoglobulins are contained in the endoplasmic reticulum cisternae. They are one example 
of protein aggregation inside cells. Aggregation of misfolded proteins is likely to occur when the 
expression  of  protein  is  much  greater  than  the  breakdown  of  misfolded  protein66. Protein 
aggregation is a problem for therapeutic antibodies because it reduces their effectiveness, and may 
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affect the quality and safety of the product. Aggregation of antibodies can occur at any of the steps 
throughout production including: cell culture, purification, formulation and storage. Antibody 
aggregation during cell culture likely affects secretion of antibody and impacts the quantity of 
antibody produced. Newly formed polypeptide chains must be properly folded59, 60. Stress in the 
endoplasmic reticulum (ER) may impact the performance of these catalysts or chaperones and 
result in misfolded proteins leading to aggregation59 or misfolding due to over accumulation of 
polypeptides in the ER, called unfolded protein response (UPR) 60. 
2.12 Previous Work 
 
Post-translational modifications can confer various properties to proteins. There’s a variety of 
modifications that can be done to the glycans such as sialylation, fucosylation, sulfation, 
galactosylation and addition or removal of GalNAc.   Most work that was done in modifying 
glycans has been in vivo. Weikert et al. engineered CHO cells by the overexpression of human 
B-1,4-galactosyltransferase and alpha-2,3-sialyltransferase39. In vitro processing has greater 
advantage due to its ability of having controlled conditions for glycan modification. Therefore, 
in vitro modification has been used to improve glycans for better delivery or enhancement of its 
therapeutic function. In 2001 Raju et al., performed in vitro galactosylation and sialyation of 
glycoproteins. Hence as described in this paper, modification using GnT3 causes for the increase 
of ADCC2. 
Taniguchi et al. have done a great deal of research on the enzymatic properties and 
biological functions of GnT341. Human GnT3 has been isolated and characterized using a human 
fetal cDNA library and has been shown that its mRNA had a size of approximately 4.7 kb. 
Human GnT3 contains 531 amino acid. Its typical domain structures include a short amino 
terminal cytoplasmic tail, a transmembrane region, and a COOH-terminal catalytic domain41. 
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Studies have shown that high mannose type oligosaccharides are not an active substrate and that 
B-1,2-GlcNAc linked to alpha-1,3-mannose is required for GnT3 activity36. Based on the kcat/Km  
values,  GnT3  specificity for  UDP-GlcNAc  is  2000  times  higher  than  other  sugar moieties36. 
Hodoniczky et. al2 have remodeled Fc N-glycans of Rituxan and Herceptin using a rat 
GnT3 produced in insect cells in vitro. In vitro remodeling of the Fc N-glycans of therapeutic 
mAb with the addition of a bisecting GlcNAc results in modulation of ADCC and not CDC.  
However, the use of galactosidase for the removal of β-1, 4-linked galactose residues can 
modulate CDC. In remodeling the N-glycan in vitro, they were able to control the selective transfer 
of a bisecting β-1,4-linked GlcNAc to the core β-linked mannosyl residue on the N-glycan. 
Furthermore this remodeled antibody had increased efficacy in vivo. A 10-fold increase in ADCC 
was achieved by the introduction of a bisecting GlcNAc to a pure G0 antibody pool2. 
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Chapter 3: Materials and Methods 
 
3.1 mAb Production 
 
3.1.1 Flask Culture 
 
Chinese Hamster Ovary1A7    (CHO) cells were cultivated in BIOGRO-CHO serum-free culture 
medium (Biogro Technologies, Manitoba, Canada) at 37°C with a 5% CO2   atmosphere, rotation 
speed of 120 rpm in a polycarbonate flask (Sigma-Aldrich, St. Louis, USA). At about 3.0 x 106 
cells/mL at passage 8, the cells were harvested and centrifuged at 500 rcf for 10 minutes. The 
supernatant containing the EG2 mAb was collected. 
3.1.2 Concentrating EG2 mAb 
 
A 400 mL Amicon Stirred Cell (Millipore) having a 10 kDa MW cut-off membrane was used 
to concentrate the EG2 mAb from culture supernatant. The supernatant was concentrated 10x 
from its original concentration. 
3.1.3 mAb Purification 
 
All mAb samples were purified using a 1 mL HiTrap Protein A column (GE Healthcare, 
Mississauga, Canada) prior to being remodeled. Briefly, the resin in the column was activated by 
the addition of the binding buffer (20 mM sodium phosphate, pH 7.0) and the samples were added 
onto the column and incubated for 4 minutes. Following a wash with binding buffer, the mAb 
was eluted with 0.6 mL of 50 mM glycine-HCl, pH 2.7. Eluted mAb was neutralized with 30 
uL of 1M Tris-base pH 8.0 (10%v/v). 
3.1.4 mAb Quantification 
 
Monoclonal antibody was quantified by high performance liquid chromatography (HPLC).  The 
particular that was used in the quantification of EG2 is POROS Protein A Affinity Columns (1 
ml). The protein A column has a specific epitope on the Fc region of the antibody. The resins 
exhibit high speed and efficiency. The samples were run on the HPLC and different fractions will 
37 
 
be eluted. The detector that was used in the HPLC is UV light at absorbance 280 nm. The peak 
which is found at approximately 4 for the EG2 antibody at a specific retention time will be 
identified and the area under the curve will then be used to calculate the concentration of EG2. 
3.1.5 Protein Analysis 
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
characterize proteins produced in culture. The proteins were prepared by dilution 1:2 into the 
sample buffer (Bis-Tris 0.24 pH 6.5; SDS 2%; glycerol 20%, DTT 50 mM) and boiled for 10 
minutes at 95°C. SDS-PAGE was performed in a discontinuous gel system with the following 
buffer composition: resolving gel: Tris-HCl 1.5 M pH 8.8 whereas stacking gel: Tris-HCl 0.5 M 
pH 8.8. It was run with running buffer (100 mM Tris, 0.01% SDS, and Glycine) at 150 V for an 
hour. The gels were stained and the bands were visualized using silver nitrate. 
Immunoblots or commonly known as Western Blots were used as analytical techniques 
to detect specific proteins in a sample. Western blots were performed on the CHO supernatant, 
cell lysate and purified EG2 that were separated on 15% SDS-PAGE gels and transferred to 
Immun-blot PVDF Membrane (Bio-rad, Canada).  Anti-Human IgG (Fc specific) goat HRP 
antisera (Sigma- Aldrich, USA) were diluted 1:100,000 with 5% wt/vol skim milk (Bio-Rad, 
Canada). The Immunoblots were developed by chemiluminescence using ECL (Amersham 
Biosciences). 
3.1.6 Cell Lysis Procedure 
CHO cell pellet were lysed using a detergent, Triton X-100 (Sigma-Aldrich, St. Louis, USA). 
Approximately 15 x 10
6 
cells were collected were centrifuged at 1200 rpm for 5 minutes at 4°C 
to obtain a pellet. Subsequently, the pellet was washed with 1x PBS three times.   The lysis 
buffer which consists of 1M Hepes pH 7.4, 5M NaCl, glycerol, Triton X-100, 0.5 M EGTA pH 
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8.0 were added to the sample and incubated on ice for 30 minutes. The cells were spun at 13,000 
rcf for 15 minutes at 4°C. The supernatant which contains the proteins are collected and used for 
further analysis. 
3.1.7 In vitro remodeling of EG2 N-glycans to produce G0 antibodies 
 
Purified EG2 mAb underwent a buffer exchange into 50 mM sodium phosphate, pH 6.0 using 
centrifugal ultrafiltration (10 kDa cutoff, Millipore, Massachusetts, USA). The samples were 
reacted with Streptococcus pneumonia ß-1,4 galactosidase (Prozyme, California, USA) and 
sialidase (Prozyme, California, USA) at 37 °C for 24 h with 1:500 ratio for enzyme:EG2 sample. 
3.2 GnT3 Production and Purification 
 
Gene Synthesis 
 
The GnT3 sequence (Appendix) was designed for gene synthesis that was ordered from Life 
Technologies (Ontario, Canada). The GnT3 gene sequence consists of BamHI and EcoRI 
restriction sites to allow for insertion of the gene into the pFastbac1 vector. It also contains TEV 
Cleavage Site to allow for the removal of the 6x His-tag (Figure 3.1). 
3.2.1 Culturing Sf9 cells 
 
Spodoptera frugiperda Sf9 cells were grown in SF900 SFM III (Gibco, Life Technologies, Ontario, 
Canada) at a shaker incubator at 27 °C and with rotation speed of 120 rpm using glass flasks. 
3.2.2 Generation of Recombinant Bacmid 
 
The baculovirus stock was amplified twice where the multiplicity of infection (MOI) that was used 
was 0.5 for both P1 and P2. For the large-scale expression of the recombinant protein of interest, 
MOI of 3 was used. 
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3.2.3 Quantification of the Virus Titer 
 
 
The plaquing medium also known as the Agarose overlay consists of 4% melted Agarose gel 
and Sf-900 SFM III Medium with 1:3 ratio. The plaque assay was performed in a 6-well plate 
with a total of 1 x 106 cells in each well. An 8-log serial dilution (10-1 to 10-8) of clarified 
baculoviral stock in Sf-900 II SFM media was prepared and infected the adhered cells on each 
well. After an hour incubation, the viral stock was removed and replaced with the Agarose 
overlay. The plates are incubated at 27 °C in a humidified incubated for approximately 7 to 10 
days. 
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Figure 3.1: Schematic representation of the GnT3 construct. This shows the 
schematic version of the full-length GnT3 and its truncated version. The truncated 
version was added into a construct with various features such as the HBM tag, TEV 
cleavage site and His tag.
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3.2.4 Production of Truncated GnT3 
 
3.2.4.1 Flask Culture 
 
The cells were seeded at 500,000 cells/mL and was grown to 2.0 x 106 cells/mL and infected 
at this point at MOI of 3. Samples were taken post infection at 24, 48 and 72 hours. 
3.2.4.2 Bioreactor 
 
The Applikon Bioreactor is a 3 L autoclavable stirred tank bioreactor was used to grow Sf9 
cells in SF900 Serum-free culture medium III. The bioreactor was operated at temperature of 
27°C, DO of 55, and Stirring speed of 100 rpm. To prevent the clumping of the cells, 0.01% 
methylcellulose was added into the culture. When the Sf9 cells have adapted to the bioreactor 
and seeded at density of 400,000 cells/mL. When the cell density reached 1.2 x 106 cells/mL, it 
was infected with the GnT3 generated baculovirus with MOI of 0.01. The Bioreactor ran for 4 
days post infection and the cells were at 24 hours and 96 hours. The cells were harvested and 
centrifuged at 500 rcf for 10 minutes. The supernatant was collected since it contains the GnT3 
protein. 
3.2.5 Concentration of the GnT3 Protein 
 
The supernatant that was collected from the bioreactor run was subjected through ultrafiltration 
using a 400 mL Ultrafiltration Stirred Cell with a 10 kDa cutoff filter (Millipore, Massachusetts, 
USA). Most of the supernatant samples were 10x concentrated after the ultrafiltration. 
Concentrated GnT3 samples were purified using a Histrap column (GE Healthcare, Ontario, 
Canada). 
3.2.6 Quantification of GnT3 protein 
 
The purity of the GnT3 was checked using SDS-PAGE stained with Silver Staining. Prior to 
use in assays, the concentration of the purified GnT3 was determined using the bicinchoninic 
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acid protein assay kit (Pierce, Rockford, USA) measuring at the absorbance of 280 nm 
calibrated with bovine serum albumin (BSA). 
3.3 Protein Analysis 
 
The Immunoblots in this experiment were performed on the GnT3 supernatant, GnT3 lysate and 
purified GnT3 that were separated on 12% SDS-PAGE gels and transferred to Immun-blot 
PVDF Membrane (Bio-Rad, Canada). The primary antibody that was used was a 6x-His 
Epitope Tag Antibody (Thermo-Scientific, Massachusetts, USA) that was diluted 1:10,000 with 
5% wt/vol skim milk (Bio-Rad, Canada). The secondary antibody was used a F(ab’) 2-Goat anti-
Mouse IgG (H+L) Cross Adsorbed Secondary Antibody (Thermo-Scientific, Massachusetts, 
USA) that was diluted 1:100,000 with 5% wt/vol skim milk (Bio-rad, Ontario, Canada). The 
immunoblots were developed by chemiluminescence using ECL (Amersham Biosciences, 
Canada). 
3.4 Glycosyltransferase Activity Assay 
 
Activity of the N-acetylglucosaminyltransferase III (GnT3) was measured using a non-
radioactive high throughput assay that utilizes nucleotidase ENTPD3/CD39L3 as a coupling 
phosphatase to remove inorganic phosphate from the leaving nucleotide disphosphate, UDP, 
generated during the glycosyltransferase reaction. The buffer that the purified EG2 samples are 
in were exchanged with 50 mM sodium phosphate, pH 6.0 using centrifugal ultrafiltration 
(10 kDa cutoff, Millipore,Billerica, USA) and the other half of the samples were exchanged 
with 25 mM MES Buffer, pH 6.7. 
For each reaction, a phosphate standard curve was generated. The assay from R&D 
systems (Minneapolis, USA) was performed in a 96 well plate and each sample, control and 
standards were done in duplicates. Both commercialized and in-house GnT3 was used to 
measure the activity of each enzymes. The commercialized GnT3 was acquired from R&D 
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systems (Minneapolis, USA) which were derived from CHO cells. The controls that were used in 
this assay include both negative and positive controls. The first negative control consist of no 
GnT3, 1 mM UDP-GlcNac, 3 µg/mL EG2. The second negative control consists of 5 µg/mL 
GnT3, 1 mM UDP-GlcNac, and no EG2. Lastly, the third negative control consists of 5 µg/mL 
GnT3, 3 µg/mL IgG, and no UDP-GlcNac. Whereas, the positive control consists of 5 µg/mL 
GnT3, 1 mM UDP-GlcNac, 3 µg/mL IgG. A coupling phosphatase control was performed where 
it only contains buffer and UDP-GlcNac. The IgG that was used in the positive control was 
produced from CHO DP-12 and obtained from University of Manitoba. The reactions were 
incubated for various time points: 30 mins, 40 mins, 50 mins and 60 mins at 37°C and then 
malachite green reagent A, deionized water and malachite green reagent B were added. The 96-
well plate is read at 620 nm at 25°C. 
3.5 mAb Glycan Analysis 
 
The EG2 antibody glycan structures were analyzed at the University of Manitoba. Briefly the 
process combine SDS-PAGE and high performance liquid chromatography (HPLC) analysis 
with the use of Exoglycosidase Array Digestions. The glycoproteins were initially visualized 
using SDS-PAGE stained with Coomassie blue. The glycoproteins were treated with Peptide-
N- Glycosidase F (PNGase F), an amidase that cleaves between the innermost GlcNAc and 
asparagine residues of high mannose, hybrid, and complex oligosaccharides from N-linked 
glycoproteins. Once released, the glycans were labelled with the fluorophore 2-aminobenzamide 
(2-AB) and run on normal phase HPLC (NP-HPLC). The elution times of glycans are expressed 
in glucose units (GU) by reference to a dextran ladder. 
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Chapter 4: Production of EG2 camelid antibody from DUKX CHO cells 
4.1 EG2 Antibody Production 
 
The CHO DUKX cell line used in this experiment produces EG2 mAb. The CHO cells were 
grown into two different media: BIOGRO (University of Manitoba) and CD-CHO Media 
(Gibco, Life Technologies). The cells were seeded at 500,000 cells/mL and were passaged 
every two days (Figure 4.1). Based on observations and calculations of the cell density, the cells 
have an average of doubling time of 19 hours. 
In parallel, the cells were left to grow for four days where they reached a cell density of 
up to 5.0 x 106 cells/mL. The EG2 mAb that are produced over the growth of the CHO cells 
are believed to increase at it reaches the later phase, therefore the cells were harvested at 
this point. The titre of EG2 was quantified using HPLC. The flask supernatant was quantified 
at 255.82 ug/mL and were purified using the protein A spin trap which is an antibody affinity 
chromatography which is specific to the Fc region of the antibody. After purification, the sample 
was quantified with HPLC where the purified flask culture is 152.81 ug/mL. 
The purified samples for EG2 including the flowthrough, two washes and the elution 
samples were ran on a SDS-PAGE gel to show the presence of the EG2 in the elution samples. 
The cell supernatant was diluted 1:10 to be loaded on the gel whereas all the other samples were 
diluted 1:2. As shown on Figure 4.2, there is a band shown at approximately 45 kDa which 
corresponds to the size of the EG2 protein. Based on the results, the culture have grown 
exponentially over the number of days. The shaker flask had a constant cell viability of over 
95%. Also, it was observed that the EG2 
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Figure 4.1: Growth curve for CHO cells in flask culture. A. Schematic graph of the design 
of the experiment where the passage number and extent of growth are studied. B. CHO DUKX 
cells were seeded at approximately 5.0 x 105 cells/mL at day 0 with a viability of 98.6%. The 
doubling time of CHO cells is approximately 19 hours and the maximum cell density before its 
passage is 3.0 x 106 cells/mL. Haemocytometer was used in counting the live and dead cells in the 
culture to calculate the cell density and viability of the culture over time up to 96 hours. The cell 
density was shown to roughly double within 24 hours, it may have lagged after day 0 since the 
cells were transferred into a new flask with fresh media. For each flask culture, one culture was 
left to grow for an additional two days to test the extent of growth. 
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Figure 4.2: SDS-PAGE of purified EG2 samples. The CHO supernatant producing EG2 
was purified using Protein A spin trap column. The samples were run on a 12% SDS-PAGE gel 
at 150 V for an hour and 15 minutes. The gel was stained using silver staining. CS is the 
culture supernatant, F1 to F5 are the flowthrough, E1 and E2 are elutions. 
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concentration for the purified samples are lower than the supernatant due to the loss of 
product during the handling of the sample for the purification. 
In order to verify the presence of EG2 in the purified samples, the samples for each 
fraction of purification: flowthrough, two washes and the two elutions were visualized on the 
SDS-PAGE. The molecular weight of EG2 is approximately 90 kDa. Although when the 
samples subjected to SDS and heat, the protein is denatured which causes for the dimer to 
become a monomer which leads for the molecular size to be approximately 45 kDa.  As  shown  
on  the  SDS  gel  (Figure  4.2),  there  was  no  bands  at approximately 45 kDa on the 
flowthrough and washes which means that the EG2 protein  is properly bound to the column. 
Due to the change of pH on the elution fractions, the EG2 protein is present and a band found at 
approximately 45 kDa. 
4.2 Aggregation of intracellular EG2 
 
Visual inspection of the morphology of CHO cells in the late exponential phase was observed 
under a Bright field with 20x magnification. Black dots were detected around the cell membrane, 
as shown in Figure 4.3. It was hypothesized that these were the result of protein aggregation. 
Further analysis was needed to identify the nature of these dots. In order to do a controlled 
and extensive study on this, different factors were studied. The first factor that was looked at 
was the type of media. Two types of media were used, Biogro and CD-CHO, in culturing these 
CHO DUKX cells. The second factor is the passage number when the black dots will start to 
show up. Lastly, the extent of growth where the CHO cells are left to grow until they reached their 
maximum cell density and if black dots will show up. 
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Figure 4.3: Bright field microscopy of CHO DUKX in Biogro media. The cells were harvested 
at 1.6 x 106 cells/mL at passage 2 with viability of 67%. Black dots emphasized with red circles 
were observed along the cell membrane. These black dots were suspected to be protein 
aggregation intercellularly. 
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The experiment was controlled by growing CHO cells in parallel with the two different types 
of media. Also, the flasks are done in triplicate. In order to observe the passage number in which 
the black dots are visible, the cell density for each flask were seeded at is 500,000 cells/mL and 
it was constantly passaged at approximately 3.0 x 106 cells/mL. Subsequently, one flask is left to 
grow until it reaches its maximum cell density to test for the extent of growth. 
The CHO cells were collected when the black dots has appeared. Its currently at passage 
number is 11 for both Biogro and CDCHO cells and no black dots were observed in cells that 
were grown to 3.0 x 106 cells/mL. Interestingly, the black dots were observed at the extended 
growth when the cells reached 5.0 x 106 cells/mL (Table 4.1 and Table 4.2). These cells were 
collected; the supernatant and pellet were separated through centrifugation at 500 rpm for 10 
minutes. The cell pellet was prepared for cell lysis using Triton X-100 detergent with protease 
(Aprotinin and Pepstatin), fucosidase (Deoxyfuconojinimycin) and glucosidase (acarbose) 
inhibitors added into the lysis solution. Following the cell lysis procedure, the cell lysate 
supernatant was collected containing all solubilized proteins. The remaining cell debris after 
Triton lysis was considered as non-soluble protein, and was resuspended in 1x PBS at pH 7.2. 
The proteins found in the resuspended lysed pellet, lysate, culture supernatant and unlysed cell 
pellet (resuspended in 1x PBS) were compared on an SDS-PAGE reducing gel as shown in 
Figure 4.4 and Figure 4.6, and by western blot analysis as seen in Figure 4.5. The western 
blot analysis used an antibody binding to the Fc region of IgG. EG2 appears at the 45 kDa mark 
on a reducing gel and bands of proteins can be seen at 45 kDa for the cell lysate, supernatant, 
and unlysed cell pellet from the western blot analysis. A band found at approximately 30 kDa in 
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purified EG2 sample was thought to be caused by long term (1 month) storage at 4°C. Although, 
further experiments should be performed such as mass spectrometry to verify this hypothesis.  
The concentration  of  EG2  found  in  each  sample  (supernatant,  lysate,  and  
insoluble proteins) were 181.93 ug/mL, 747.14 ug/mL, 123.25 ug/mL respectively. Once the 
samples were purified and the amounts of EG2 were quantified, the glycan forms that were 
found in antibody pool was investigated. All three samples: supernatant, lysate and insoluble 
proteins were sent to University of Manitoba for glycan analysis. Based on the glycan analysis 
shown in Figure 4.7, glycans in each sample were unique. Fucosylated glycoforms were 
found in the supernatant fraction while more complex glycoforms with more sugar moieties 
were found in the lysate and insoluble proteins. 
Based on the experimental results, the visual inspection of CHO cells in the late 
exponential phase using an inverted light microscope revealed that there were signs of protein 
aggregation within the cells (Figure 4.3) which were identified as black dots. The stained SDS 
gel (Figure 4.6) showed a band around 45 kDa in samples of the solubilized pellet. Western 
blot (Figure 4.5) verified that this was EG2 protein. The EG2 present in the sample was 
quantified using HPLC and it was shown that most of the EG2 was found in the cell lysate. This 
showed that the overproduction of the protein caused the antibodies to aggregate and stay 
within the membrane of the cell. The aggregated proteins may be what others referred to as 
Russell Bodies. 
One of the major questions that was asked is what caused these proteins to be stuck 
inside the membrane. A glycan analysis on the samples was performed to show whether or not 
PTMs affected the ability of each protein to be secreted. Based on the analysis (Figure 4.7), 
most of the glycoforms which contained fucose were found in the supernatant; whereas, the 
less complex glycoforms were found in the cell lysate or to be part of the insoluble proteins. 
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Therefore, it was identified that the black dots are the aggregated EG2 that were 
overproduced within the cell. The exact cause of the aggregates is still under investigation. To 
further investigate the identity of these black dots, immunofluorescent staining can be 
performed in these cells and CHO cells that do not produce EG2 mAb. Thus, in looking at the 
three factors that may have been causing these black dots, it can be postulated that it can be 
due to the sufficiency of nutrients present in the media. Also, the passage number and extent 
of growth where the cells are reaching their maximum density and the viability of the cells 
are decreasing which may lead to a mechanism which causes the antibody to aggregate. 
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Figure 4.4: Coomassie Blue staining of SDS-Gel with different samples from cell lysis. The 
cells that was harvested were separated using a centrifuge at 500 rpm for 10 minutes. The cell 
pellet was subjected to lysis using a lysis solution with Triton X-100. The different samples 
were run on the gel including the purified EG2 that were dilution into 1/10, 1/100, and 1/1000 
but Coomassie stain is not sensitive enough to detect them. The other samples that were run on 
the gel were insoluble proteins, lysate, cell supernatant, cell pellet and GnT3 cell lysate as a 
negative control. In all of the samples, there is a band observed at approximately 45 kDa that 
can be identified as EG2. 
 
 
 
 
 
 
 
 
 
53  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Western Blot analysis on samples from cell lysis. The samples from the cell pellet 
that were subjected to cell lysis were separated using 15% SDS-gels. The order that the sample 
was loaded on the gel is exactly the same for the gel that was stained with Coomassie blue. 
After the SDS-PAGE, the samples were transferred into a PVDF membrane and probed with 
Anti-Human IgG (Fc specific) goat HRP antisera. Bands showed up at around 45 kDa for the 
1/10 EG2, Cell lysate, cell supernatant and cell pellet samples which is identified to be EG2. 
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Figure 4.6: Coomassie Blue staining on purified samples.  The insoluble proteins and cell 
lysate were purified using protein-A spin trap. The flowthrough, washes and elutions for both 
samples were run on a 15% SDS gel and stained with Coomassie blue. Purified EG2 was used 
as a positive control. There was a band at approximately 45 kDa that was identified for the first 
elution on the cell lysate that shows the presence of EG2 in the cell lysate. 
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Figure 4.7: Glycan Analysis of the EG2 supernatant, lysate and pellet. Prior to the glycan 
analysis, each EG2 lysate sample was subjected to cell lysis using Triton x-100. A buffer 
exchange was performed on those samples since Triton X-100 is a detergent so it may interfere 
with the column. The Glycan analysis was performed using a protein A column and HPLC. 
The process was previously described in the thesis 
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Table 4.1: Number of Black Dots per cell recorded 
 
 
 
 
 
 
 
 
 
 
Table 4.2: Cell Density when the Black Dots first appeared for both media 
 
 
 
 
 
 
 
 
Type Passage 
# of Black Dots/# 
of Total Cells Cell Density 
 
Cell Viability 
Biogro 1 23/108 3650000 68% 
CDCHO 1 0/104 9950000 93% 
Biogro 2 32/140 1180000 43% 
CDCHO 2 2/168 11575000 98% 
Biogro 3 19/107 4121250 69% 
CDCHO 3 3/292 4720000 87% 
Biogro 4 8/154 4252500 73% 
CDCHO 4 0/145 9450000 99% 
Biogro 5 9/40 1370000 95% 
CDCHO 5 23/137 4640000 87% 
Biogro 6 26/89 3412500 65% 
CDCHO 6 9/116 3176250 27% 
Biogro 7 16/61 2825000 57% 
CDCHO 7 8/60 5325000 57% 
Type Passage Cell Density Cell Viability 
Biogro 1 5220000 95% 
CDCHO 2 7840000 98% 
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Chapter 5: Production, Quantification and Purification of N-
Acetylglucosaminylferase III (GnT3) and Testing its Activity 
 
5.1 Production and Purification of GnT3 
 
A feature that was added is the honeybee melittin (HBM) which allows for the enzyme to be 
secreted and properly glycosylated that will allow for the GnT3 to be active. Once the protein 
was successfully expressed, an IMAC column was used to purify the protein with 6x His tag. 
Lastly, a TEV cleavage site is added which is used for controlled cleavage of the fusion of the 
6x His tag protein to the GnT3 protein. 
Comparably the bioreactor was seeded at 500,000 cells/mL and since the cells were 
originally growing in a flask, the cells had to adapt when it was grown in a bioreactor. The viability 
of the cells after the inoculation of the cells on the bioreactor dropped. Other than the adaptation 
of the cells to the bioreactor, this may have been caused by the fact that there was no heating 
jacket to maintain the temperature to 27°C. Therefore as an alternative, the bioreactor vessel was 
placed into a 27°C water bath. As previously stated, the conditions that are regulated for the 
growth of the Sf9 insect cells are the temperature, stirring speed, and DO. Due to the lack of 
heating pad, the temperature only reached up to 25°C that may have slowed down the growth 
of the insect cells. Also, the DO level was set to 55% but it was fluctuating throughout from 30% 
to 75%. The cells ran for four days prior to infection until cell density reached 1.2 x 106 cells/mL, 
the Sf9 insect cells were infected with the Gnt3 baculovirus. Once the cells were infected, the cells 
stopped growing and the cell viability started to decreased. The cells were left for four days 
post infection until it reached the cell viability of 73% when it was collected (Figure 5.1). 
After the samples were collected, they were concentrated 10x and followed by purification of the 
GnT3 protein that was produced using Histrap column. Although before the purification, a   
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Figure 5.1:  Growth Curve of Sf9 cells in an autoclavable Bioreactor. The Sf9 cells were 
seeded at approximately 5.0 x 105 cells/mL at day 0 with a viability of 99%. The doubling time 
of Sf9 cells is approximately 20 hours and the maximum cell density it can reach is about 8.0 x 
106 cells/mL. Haemocytometer was used in counting the live and dead cells in the culture to 
calculate the cell density and viability of the culture over time up to 96 hours. The cell density 
was shown to roughly double within 24 hours, it may have lagged after day 0 since the cells were 
transferred into a new flask with fresh media. Once the cell viability reached 1.2 x 106 cells/mL, 
the cells were infected with the GnT3 baculovirus with MOI of 0.01 for protein production.  
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buffer exchange was performed on the supernatant to change the media Sf900 SFM III into the 
binding buffer for the Histrap purification is consists of 20 mM Tris-HCl, 8 M urea, 500 mM 
NaCl, 5 mM imidazole, pH 8.0.   It was determined that there are contents from the Sf900 SFM 
III media that will interfere with the resin of the Histrap column. The supernatant, cell lysate, all 
the fractions of purification were visualized using SDS-PAGE and stained with silver staining 
(Figure 5.2). The purified samples were quantified using BCA Assay and it was determined to 
be 1.8 ug/mL for the flask culture and 67.9 ug/mL for the bioreactor run. For further analysis, 
the proteins were transferred onto a PVDF membrane and were probed with antibodies specific 
to the His-tag. Unfortunately, no bands showed up not even for the positive control that was 
used: a calmodulin protein with 6x-Histag. 
The GnT3 protein that was synthesized was truncated at glutamine 25 since the 
transmembrane domain was needed to be removed which is located prior to the amino acid 
residue 25. This allowed for the protein not to get stuck in the membrane when it was produced 
within the cell. It was previously stated that GnT3 protein needs to be secreted in order to get 
properly glycosylated. Therefore, a honey bee melittin (HBM) tag was added to the construct. 
Honey Bee Melittin secretion signal allows for efficient translocation of proteins into the ER in 
Spodoptera frugiperda (Sf9) cells69. Another feature that was added was the 6x His-tag at the C- 
terminus. This allows for the purification of the protein using affinity chromatography. In order 
to get a properly folded protein, a TEV cleavage site was added preceding to the 6x His-tag so it 
can be easily removed after purification. 
Since the production of proteins in insect cells in a flask does not give a huge amount 
of proteins, the infection of Sf9 cells were up scaled into a bioreactor. After doing the plaque 
assay, the titre of the virus was identified and a low multiplicity of infection was performed. 
Low MOI infection was performed since it is feasible due to the amount of virus needed. 
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Figure 5.2: Visualization of GnT3 protein using SDS-PAGE. The protein samples were run 
on 12% SDS gel at 150 V for an hour and fifteen minutes. The gel was stained using silver 
nitrate. The legend is described on the side of the image. There were three negative controls used 
which are lanes 9 to 11. It was a different baculovirus infecting the Sf9 cells. .Also, having a low 
MOI lets the cells grow for a longer periods of time since it will take longer to infect all of the 
cells in the culture. 
 
 
 
 
 
 
 
 
 
 
61  
After the production of GnT3, the proteins were harvested and purified using Histrap 
columns. According from previous studies, the SF900 SFM III media might interfere with the 
resins on the Histrap columns therefore a buffer exchange is needed. The harvested supernatant 
was exchanged into the binding buffer in order to prevent interference during purification. In 
order to verify that there is a pure sample, all the elutions were ran on a 12% SDS-PAGE gel and 
stained with silver staining. There were no protein bands present on the elution lanes (Figure 
5.3). Therefore, the concentration of the purified samples were measured using the BCA Assay 
and it was shown that the amount of proteins that are loaded into each well is approximately 16 
ng. Even though the gel was stained using silver nitrate which is highly sensitive (can detect 
as low as 25 ng), no band has appeared. Therefore, instead of just doing a 40x concentrate, it 
was increased to 200x that resulted for the appearance of the GnT3 band at approximately 68 
kDa. 
For the western blot analysis, no band showed up even for the positive control which 
showed that there might have been a problem with the antibodies that were used specific to the 6x 
Histag. One of the concern is the secondary polyclonal antibodies. As previously described, 
polyclonal antibodies are produced from different B cell lineages which allow for recognition 
of multiple epitopes. Therefore, there is a possibility that the secondary antibody that was used 
was produced in various lineages except for the one that is compatible with the insect cells since 
GnT3 is produced in insect cells. 
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Figure 5.3: SDS-PAGE gel of purified GnT3. The protein samples were ran on 12% SDS 
gel at 150 V for an hour and fifteen minutes. The gel was stained using silver nitrate. M is 
marker, 1 is Sf9 supernatant, 2 is pellet resuspended in 1x PBS, 3 is Flowthrough, 4 to 6 are 
washes, 7 is the elution, 8 to 11 are negative controls which are another Sf9 infected cultures. 
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5.2 Activity of GnT3 
 
Even though there was no band that showed up for the western blot, the activity of GnT3 was 
tested using the glycosyltransferase assay. Due to the contents that the SF900 SFM III media 
might have which will interfere with the assay, a buffer exchange to 1X Assay Buffer was 
performed on the in-house GnT3 that was produced from Sf9. The calibration curve that was 
used in this assay consisted of a phosphate standard curve dissolved in 1X Assay Buffer 
(Appendix). 
In order to make sure that the activity that is being measured is accurately from the 
GnT3 enzyme, controls were executed while doing this assay. The positive control consisted of 
using another acceptor substrate which is the IgG DP-12 clone 1934 from Maureen Spearmann 
at University of Manitoba instead of the EG2 mAb. Various negative controls were performed 
in this assay. The first major ones was No GnT3 enzyme, no donor substrate and no acceptor 
substrate. Additionally, a negative control which consists of another baculovirus infected culture 
other than the GnT3 virus to make sure that there are no enzyme in the culture which gives a 
positive reading. The activity of GnT3 was calculated using a phosphate calibration curve 
(Figure 5.4 and Figure 5.5). 
As shown in the graphs for Figure 5.4 and Figure 5.5, there’s a visible decrease of 
enzyme activity as the incubation time gets longer. Also, the negative controls gave small 
absorbance readings that the activity observed in these wells were considered negligible. The 
positive control shows a great enzymatic activity for the GnT3 towards a different acceptor 
substrate. Since there was a decrease in activity, another factor that should be studied is the 
concentration of the acceptor substrate that is present in the reaction (Figure 5.6). Lastly, the 
in-house GnT3 that was used in the previous reactions is the crude supernatant. Therefore, the 
GnT3 supernatant was purified using a Histrap column since the GnT3 protein has a 6x His tag 
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Figure 5.4: GnT3 enzyme activity with various times. The GnT3 reaction was incubated at 
different times to acquire the ideal time for the highest activity. Two types of EG2 that were 
used: EG2 G0 antibody which means that the terminal sugars were removed and native EG2. 
The concentration of the acceptor substrate that was used is 2 ug/mL and 1 mM donor substrate. 
The in-house GnT3 that was used is a crude sample. 
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Figure 5.5: GnT3 enzyme activity with various times. The GnT3 reaction was incubated at 
different times to acquire the ideal time for the highest activity. Two types of EG2 that were 
used: EG2 G0 antibody which means that the terminal sugars were removed and native EG2. 
The concentration of the acceptor substrate that was used is 4 ug/mL and 1 mM donor substrate. 
The in-house GnT3 that was used is a crude samples. 
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Figure 5.6: GnT3 enzyme activity with different concentrations of acceptor substrate. The 
GnT3 reaction was incubated at two different concentration of EG2: (a) 2 ug/mL and (b) 4 ug/mL 
to identify whether the enzymatic activity will increase with increase of acceptor substrate 
concentration.  Two types of EG2 that were used: EG2 G0 antibody which means that the 
terminal sugars were removed and native EG2. The concentration of the acceptor substrate that 
was used is 4 ug/mL and 1 mM donor substrate. The in-house GnT3 that was used is a crude 
sample. 
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As previously described, the folding of the protein is vital in the enzymatic activity of 
an enzyme. For this experiment, the GnT3 had an HBM tag to ensure that it is secreted 
properly for the enzyme to be properly glycosylated in the three potential N-glycosylation 
sites. Thus, the activity of the GnT3 enzyme was measured using an assay that utilize the by-
product of the reaction which is the nucleotide. A phosphatase is used to release a free phosphate 
which is directly proportional to the activity of the enzyme. 
For every assay, there should always be controls that are executed. The positive control 
which involves the use of another acceptor substrate instead of EG2 mAb. This control was 
chosen to ensure that if there was no activity detected, that it wasn’t because of the acceptor 
substrate. Thus, it makes sure that the active site is not buried in the EG2 protein since it has 
a mutation in the Fc region which may affect the protein folding. The first three negative 
controls are common since it is assumed that no activity should be detected if any of the factors 
that are involved in the reaction is not present. Whereas, the last two controls where a crude 
supernatant and purified baculovirus infected culture was used in the reaction instead of the 
GnT3. This allows for the verification that there is nothing in the Sf9 culture or media that 
contributes to the activity that was being detected by the assay. 
Two factors that were studied in this assay are: time and concentration of acceptor substrate. 
For the study involving time shown in Figure 5.4 and Figure 5.5, there was a noticeable 
decrease in the enzyme activity as the time increases. This trend might have occurred due to 
the fact that there is not enough acceptor substrate in the reaction. Therefore this has led to 
increasing the acceptor substrate to double. Although, as seen in Figure 5.6, the enzymatic 
activity was not observed to have doubled even if the acceptor substrate increased by double. 
Therefore, there’s another factor that should be studied which is the donor substrate. The GnT3 
enzyme does not fall under the Michaelis Menten type mechanism but it can be hypothesized 
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to fall under the ping pong mechanism. The ping pong mechanism is a double-displacement 
reaction where the enzyme change into an intermediate form prior to the formation of the 
product71. This reaction may fall into this category since it involves three factors: enzyme, 
donor and acceptor substrate. Another key feature to this mechanism is that one product is 
formed and released before the second product substrate binds. In perspective, the GnT3 
enzyme forms a temporary complex (intermediate) with GlcNac from UDP-GlcNac (donor 
substrate). The first product will then be released which is the UDP prior to the transfer of 
GlcNac to the monoclonal antibody (acceptor substrate) 
 The activity of the GnT3 enzyme can be measured using an assay which relates the 
release of free phosphate from the nucleotide to the enzymatic activity. The positive control gave 
a huge amount of activity whereas the values that were acquired for negative controls were 
negligible. The trends that were observed was a decrease in activity as the post incubation time 
increases which led to a subsequent experiment in doubling the concentration of the acceptor 
substrate. Although, this change did not give the expected results. Therefore, there might have been 
a shortage of UDP-GlcNac as well which hinders the activity of the enzyme. Lastly, a pure GnT3 
enzyme must be used to avoid interferences in the absorbance readings of the assay. 
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Chapter 6: Conclusion and Future Work 
 
 
 The purpose of this project was to modify this antibody population in vitro to have a 
uniform glycoform. The specific glycan that was modified is the EG2 antibody that was 
produced from CHO DUKX cells. It was shown that the overproduction of the antibodies may 
have led to the aggregation of the protein. This was observed through the presence of black dots 
looking at the CHO cell under an inverted light microscope. The identity of the different 
morphology of these cells were tested through SDS-PAGE, column purification using protein-
A column and western blot. Further analysis must be performed in order to verify that the black 
dots that were observed are in fact EG2. Immunofluorescent staining can be completed 
through the use of antibodies that are specific to the Fc region of EG2 which are conjugated 
onto a fluorescent protein which can be observed under the confocal microscope. If the black 
dots fluoresce, it can be concluded that the aggregated proteins are EG2. 
 Based on this report, the glycan patterns have been hypothesized to have an effect on the 
proper secretion of EG2 antibodies based on the glycan analysis that was performed. Therefore, 
an additional factor that can be studied is the production of EG2 in a specific cell line. An 
alternative cell line is Sf9 insect cells, since the glycan patterns that are produced in insect cells 
are less complex.  The glycans produced by insect cells are less complex since they do not have 
a glycan pattern with fucose, sialic acid and galactose. Therefore, if black dots are also observed 
in insect cells, this can verify the hypothesis that the absence of fucose or galactose affects the 
aggregation and secretion of the antibodies. 
 The enzyme that was used for the in vitro modification was the N- 
acetylglucosaminyltransferase III (GnT3). GnT3 catalyzes the transfer of bisecting GlcNAc into 
the mannose core region of glycan. Throughout this project, the GnT3 enzyme was 
synthetically synthesized in Sf9 insect cells. The presence of GnT3 was verified using different 
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techniques such as SDS-PAGE and western blot. Lastly, the activity of the GnT3 enzyme was 
measured using glycosyltransferase activity assay. The activity assay showed activity for the 
in-house GnT3 although it was observed that higher concentration of the enzyme is needed to 
properly test and measure its activity. 
As previously stated in this report, the GnT3 that was produced from Sf9 insect cells 
after purification has a low concentration. Therefore, a different method in changing the buffer 
is needed to obtain higher recovery. Another bioreactor run should be performed in order to 
produce more GnT3 protein, then the enzyme can be purified and then be used to modify the 
antibody population. Glycan analysis is needed in order to verify that the EG2 antibody 
population was uniformly transformed into having a glycan pattern with a bisecting GlcNAc. 
The main struggle for this part of the project is the production of high amounts of GnT3 
protein which can be the bottleneck of successful in vitro modification of the EG2 antibody. 
Another limitation that was faced is that, the acceptor substrate, EG2 was not expressed as 
much as it was expected due to the aggregation that was observed. Therefore, a lot of questions 
arose throughout my master’s thesis; 
- Is the active site for the EG2 buried due to the mutation at the Fc region, that 
GnT3 is not able to catalyze the addition of bisecting GlcNAc? 
-     Would it be better to use a commercial antibody such as Rituxan and Herceptin? 
 
- What additives can be added to the media in order to prevent for nutrition 
starvation which might have caused the aggregation? 
-    Would high MOI or low MOI be better for protein production? 
 
- What buffer can be used that is general for all reactions and purification 
that are performed prior to the testing of the GnT3’s activity in order to prevent for 
the loss of the protein? 
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The work demonstrated in this thesis can be used as a tool in expanding the in vitro 
modification of the glycans. The first step is understanding how the EG2 is folded and how this 
can affect any inhibition for the addition of bisecting GlcNAc. Also, try another type of IgG 
antibody such as Rituxan and Herceptin to test whether the uniform population of glycan 
patterns in the antibody population will be achieved. At the same time, the production of GnT3 
should be optimized. This can be done through doing an infection with various high MOIs and 
identifying which will result to a highest protein production. Once the ideal MOI was identified, 
more GnT3 baculovirus will be generated in order to do a bioreactor run. A bioreactor run  
producing GnT3 is required in order to acquire higher concentration of proteins. Also, doing 
optimization of the concentration of imidazole is needed to acquire the purest GnT3 protein. In 
having a pure GnT3 enzyme stock, it would be easier to detect the concentration of enzyme and 
its activity. 
After the verification of the activity of GnT3 and its ability to modify the glycoform 
to achieve a uniform antibody population, a process can be outlined an efficient process of 
producing human GnT3. Thus, this can be up-scaled to industry level by attaining the perfect 
conditions that will allow remodeling of antibodies directly from culture supernatant using 
immobilized glycosyltransferases. 
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Appendix 
 
Molecular Cloning of GnT3 with HBM secretion tag  
Human N-acetylglucosaminyltransferase III (GnT3) has a molecular weight of approximately 60 
kDa and is highly conserved between human, rat, chimpanzee, cow, mouse, chicken and zebra 
fish. The main function of this enzyme is it catalyzes the transfer of GlcNAc to the core β-
mannosyl residue on an acceptor N-glycan (Figure 1). The reaction can be inhibited by the 
presence of β-1,4-gal residue on the Manα-1,3 branch. It has a transmembrane domain shown in 
blue below, and a glycosyltransferase catalytic domain shown in green in the diagram below 
(Figure 2).  
 
Figure 1: Reaction catalyzed by GnT3.  
 1 MKMRRYKLFL MFCMAGLCLI SFLHFFKTLS YVTFPRELAS LSPNLVSSFF WNNAPVTPQA 
       61 SPEPGGPDLL RTPLYSHSPL LQPLPPSKAA EELHRVDLVL PEDTTEYFVR TKAGGVCFKP 
      121 GTKMLERPPP GRPEEKPEGA NGSSARRPPR YLLSARERTG GRGARRKWVE CVCLPGWHGP 
      181 SCGVPTVVQY SNLPTKERLV PREVPRRVIN AINVNHEFDL LDVRFHELGD VVDAFVVCES 
      241 NFTAYGEPRP LKFREMLTNG TFEYIRHKVL YVFLDHFPPG GRQDGWIADD YLRTFLTQDG 
      301 VSRLRNLRPD DVFIIDDADE IPARDGVLFL KLYDGWTEPF AFHMRKSLYG FFWKQPGTLE 
      361 VVSGCTVDML QAVYGLDGIR LRRRQYYTMP NFRQYENRTG HILVQWSLGS PLHFAGWHCS 
      421 WCFTPEGIYF KLVSAQNGDF PRWGDYEDKR DLNYIRGLIR TGGWFDGTQQ EYPPADPSEH 
      481 MYAPKYLLKN YDRFHYLLDN PYQEPRSTAA GGWRHRGPEG RPPARGKLDE AEV 
 
Figure 2: Human GnT3 Protein Sequence.  
 
In order for the enzyme to be fully active, it has to be prevented from binding to the membrane. 
Therefore, the GnT3 enzyme that would be expressed is truncated at position 61 where the 
transmembrane was removed from the sequence.  
 
Since the Baculovirus system will be used to express this enzyme, the vector that will be used is 
the pFastBac1 vector (Figure 3).  The Bac-to-Bac TOPO Expression System consists of the 
pFastBac plasmids which allow for the rapid generation of an expression construct containing 
the gene of interest which under the control of a Baculovirus-specific strong polyhedron (PH) 
promoter. The E.coli host strain that was used is DH10Bac which contains a Baculovirus shuttle 
vector (bacmid) and a helper plasmid, which allows for the generation of a recombinant bacmid 
following transposition of the pFastBac expression construct.  
 
Prior to retransforming of the plasmid with GnT3 into the DH10Bac system, it is transformed 
into an amplifying vector which is the Top10 cells. Top10 cells are ideal for high-efficiency 
cloning and plasmid propagation. It also allows for stable replication of high-copy number 
plasmids. After the plasmid with GnT3 has been successfully amplified with the Top10 cells, the 
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purified plasmid will be retransformed into the DH10Bac where it would be recombined into the 
Baculovirus.  
 
 
 
Figure 3: Schematic map of pFastBac1 vector 
 
A couple of different ways were tried in order to generate an active GnT3 enzyme.  
 
First: Conventional Molecular Cloning 
 
Prior to the generation of the Baculovirus, the gene of interest, the truncated GnT3 was amplified 
using polymerase chain reaction using pAcSG2_GnT3 template and the following primers and 
conditions:  
 
Forward primer:   
               EcoRI          Glu61                Truncated CDS 
5’ GCACTGTCTAACGTACTCATAGCGAATTCATGGAGCCAGGAGGCCCTGACCTGCT 
3’ 
 
Reverse primer:   
                 XhoI  6 x His Tag 
5’ CAATCTCGAGCTAGCCGTGATGGTGATGGTGATGGCCgacttccgcctcgtccag 3’ 
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Table 1: PCR Conditions 
 
Cycles Temperature Time 
Di 98 Celsius 30 seconds 
D 98 Celsius 15 seconds 
A  69 Celsius 15 seconds 
E 72 Celsius 1:45 seconds 
Ef 72 Celsius 5 minutes 
 
Table 2: Composition of the PCR reaction 
Composition Volume 
H2O 37.3 uL 
5x HF Buffer 10 uL 
10 mM dNTPs 1 uL 
100 uM Forward Primer 0.25 uL 
100 uM Reverse Primer 0.25 uL 
Phusion Polymerase  0.2 uL 
Template from pAcsG2 1 uL 
 
The gene of interest, GnT3, was properly amplified shown in the following figure: 
  
Legend: 
Lane M: 1 kbp Marker [kbp]                GnT3       
Lane 1: tGnT3-His (Start)                                                
Lane 2: tGnT3-His (Start)      
Lane 3: tGnT3-His (Fusion) 
Lane 4: tGnT3-His (Fusion) 
Lane 5: tGnT3-His (Start) 
Lane 6: tGnT3-His (Start) 
 
 
 
 
 
 
Figure 4: 1% Agarose Gel of the amplification of GnT3 gene 
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In order for the GnT3 to be secreted and properly glycosylated, honeybee melittin (HBM) tag is 
needed. This was amplified using overlapping PCR. The primers that were used are overlapping 
28 bp and no template is needed in generating the product. The primers and conditions that were 
are used for this PCR are the following: 
Primers: 
FWD_HBM-Overlap 
             BamHI 
5’ 
ATGGATCCGCTAGCATGAAATTCTTAGTCAACGTTGCCCTTGTTTTTATGGTCGTAT
ACA 
REV_HBM (O2) 
              EcoRI 
5’ 
ATGAATTCTCGATCCGCATAGATGTAAGAAATGTATACGACCATAAAAACAAGGGC
AACG 
Table 3: Two step protocol (30 cycles) for HBM PCR Conditions 
Cycles Temperature Time 
Di 98 Celsius 30 seconds 
D 98 Celsius 15 seconds 
A/E 72 Celsius 20 seconds 
Ef 72 Celsius 5 minutes 
 
 
Figure 5: 3% Agarose gel of HBM Tag 
For both PCR reactions, Phusion polymerase was used. After acquiring the amplified products, 
gel extraction purification was performed to isolate the desired fragment of the intact DNA.  
After the DNA purification, the purified PCR products were digested with specific restriction 
enzymes shown in the following figure.  
Digested the HBM fragment with BamHI and EcoRI at 37 degrees Celsius for an hour (Slow 
Digest) 
 
 
 
BamHI EcoRI 
HBM 
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Digested the GnT3 fragment with EcoRI and XhoI at 37 degrees Celsius for an hour (Slow 
Digest)   
 
 
 
After the digestion of the DNA fragments, ligation was performed. The initial approach to the 
ligation is having a 3:1 ratio of the DNA products to the pFastbac1 vector. In this approach, the 
GnT3 was successfully ligated in the pFastbac1 vector. After digestion diagnostics and 
sequencing this was confirmed. Therefore, the ligation of HBM tag and pFastbac1_GnT3 vector 
was performed in having a 3:1 ratio as well of the HBM DNA product to the pFastbac1 vector. 
Although this approach has not been successful therefore another approach was done. The 
second approach is the ligation of the two DNA products: GnT3 and HBM PCR products in 
having a 1:1 ratio and ligating the GnT3 with HBM tag into pFastBac1 vector with a 3:1 ratio of 
the DNA to the vector. The ligated products were transformed into Top10 E.coli cells using the 
heat shock method. The negative plate consists of just the Top10 E.coli cells without the vector, 
therefore no colonies showed up. The positive plate consists of the Top10 E.coli cells with the 
pFastbac1 vector without the insert and a lawn of colonies showed up. Lastly, the plate with 
pFastbac1 with the insert have shown a couple of colonies and colony PCR was performed on 
these colonies. There were possible positive colonies that may have the vector with the insert.  
 
The following figure shows the colony PCR of the pfastbac1_Gnt3+HBM 
 
 
The primers that were used for this diagnosis are specific to the GnT3 gene therefore the product 
was found approximately at 1482 bp. The negative control had pFastbac1 without the insert and 
EcoRI XhoI 
tGnt3 
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no band showed up. On the other hand, colonies 4, 6 and 7 shows insertion of the tGnT3His with 
HBM.  
The vector DNA from the positive colonies were isolated using mini-prep and were digested 
with EcoRI and XhoI restriction enzymes for a diagnostic restriction digest test. The following 
figure shows the 1.5% Agarose gel of the diagnostic restriction digest.  
 
Legend: 
M: Marker 
1 – 4: Colonies digested with EcoRI/XhoI 
5: Negative control: pFastbac1 without insert 
 
Colonies 3 and 4 were sent for sequencing although the results showed that the gene of interest 
was not properly ligated into the vector. Another restriction digest diagnostic was performed 
with different restriction enzymes in order to confirm the validity of the presence of the 
pfastbac1 vector with GnT3_HBM gene. The following figure shows the restriction digest 
diagnostic: 
 
Expected gel results: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BamHI KpnI EcoRI/BamHI EcoRI 
EcoRI/XhoI XhoI 
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Actual gel result: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Also, another PCR amplification with the mini-prep was performed using different primers 
where the forward primer is specific to sequence 300 bp before the HBM tag and the reverse 
primer is specific to the GnT3 gene. The following figure shows the amplified gene product at 
approximately 1870 bp for the tGnT3 with HBM enzyme.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M  1   2   3   4   5   6   7   8   9   10  11  12  13  14   
M: Marker 
1: A BamHI 
2: B BamHI 
3: A KpnI 
4: B KpnI 
5: A EcoRI/BamHI 
6: B EcoRI/BamHI 
7: A EcoRI 
8: B EcoRI 
9: A KpnI/NotI 
10: B Kpn/NotI 
11: A EcoRI/XhoI 
12: B EcoRI/XhoI 
13: A Xho 
14: B Xho 
250 
500 
750 
1500 
GnT3 (1482 bp) 
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Legend: 
Negative Control: no template; has all buffers, dNTPs, Taq polymerase  
Positive Control: pAcSG2-Gnt3 template, all buffers, dNTPs, Taq polymerase 
Lanes 1 – 4: Four different samples of mini-prep from various positive colonies 
(pFastbac1 with tGnt3 + HBM) with Phusion 
Lane 5: Mini-prep sample of the positive colony for pfastbac1 + tGnT3 with Taq 
polymerase 
250 
500 
750 
1000 
1500 
2000 
Kbp 
M    1       2      3     4     -      +      5     
tGnt3 + HBM 
(1870 bp) tGnt3 
(1480 bp) 
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Second: Fast Cloning 
Fast cloning is where the vector is initially linearized and then the primers that were used had a bit of the vector and 
the gene of interest. The following figure briefly explains the process of Fast Cloning.  
 
This idea was approached due to the restriction digests and ligation problems that were 
encountered since this approach does need restriction digestion and ligation. The primers that 
were used are the following: 
Forward Primer: 
5’CTTGTTTTTATGGTCGTATACATTTCTTACATCTATGCGGAATTCatggagccagga
gg 
Reverse Primer: 
5’GACCATAAAAACAAGGGCAACGTTGACTAAGAATTTCATTTCGGACCGGGA
TCCGCGCC 
Although, this protocol did not work as well.  
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Third: Megaprimer PCR 
Lastly, the last approach that was performed is megaprimer PCR. Megaprimer PCR is a method 
that involves two rounds of PCR which utilize “flanking” primers and one internal mutagenic 
primer containing the desired base substitution. Unlike other two step protocols, which uses 
Agarose gel electrophoresis whereas in megaprimer PCR this can be eliminated. It has been 
eliminated through the use of primers with significantly different melting temperatures to initiate 
the PCR steps which will ensure the selective synthesis of the only two primers present in the 
reaction. This approach consists of multiple PCR reactions and DpnI digest. The primers that 
were used are the following: 
Forward Primer: 
ACCATCGGGCGCGGATCTCGGTCCGAAACCATGAAATTCTTAGTCAACGTTGCCCTTGTT 
 
Reverse Primer: 
AAGCGGCCGCACTAGTTGAGCTCGTCGACGCGCATAGATGTAAGAAATGTATACGACCAT 
 
Unfortunately, this approach didn’t work as well. There were no positive colonies present when 
transformation using heat shock was performed.  
 
 
Additional Update 
The previous colonies that were shown to be positive, the plasmid were isolate using the 
miniprep kit. It was amplified using Phusion and Taq polymerase to compare whether the band is 
more intense due to the polymerase or due to the amount of DNA in the miniprep 
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Legend:  
M - Marker 
1 and 5 – Colony 1 
2 and 6 – Colony 4 
3 and 7 – Colony 5 
4 and 8 – Colony 6 
+ - positive control (pFastbac1)  
- - negative control (no template)  
 
As shown on the gel, the bands from the Phusion enzyme is more intense than the Taq 
polymerase. Although, there not that much difference between the intensities.  
 
 
Reamplification of HBM Tag 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: M – Marker, 1 – HBM PCR Product, 2 – No Template 
The HBM tag was generated using overlapping PCR with the same conditions stated in Table 3. 
The PCR product was purified using the PCR kit and another Agarose gel electrophoresis was 
performed in order to make sure that there is enough DNA found in the solution after 
purification.  
 
                                                                                                      Legend: 
                                                                                                      M – Marker 
                                                                                                        1 and 2 – Purified HBM 
Product 
                                                                                                        + - Unpurified PCR Product 
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According to the PCR protocol, 100% isopropanol must be added if the DNA size is less than 
500 bp, due to this the sample would not settle at the bottom the wells therefore as seen on the 
gel, there were no bands at around 90 bp.  
Therefore, it was assumed that there are still DNA present in the sample and the digestion of the 
enzymes is performed.  
Table 4: Components of Digestion Reaction 
Fast Digest (BamHI/EcoRI) 
 Double Digest 
Water 16 uL 
10x Buffer 2 uL 
Enzymes (BamHI/EcoRI) 1 uL of each 
DNA 10 uL 
Total 30 uL 
 
Slow Digest (EcoRI/XhoI) 
 Double Digest 
Water 11 uL 
5x Buffer 5 uL 
Enzymes (BamHI/EcoRI) 1 uL of each 
DNA 10 uL 
BSA 3 uL  
Total 30 uL 
 
The samples were incubated at 37 degrees Celsius for 5 hours and overnight. Then the enzymes 
are deactivated at 80 degrees Celsius.  
After the enzymes were deactivated, the ligation reaction on the samples were performed 
 
Table 5: Components of Ligation Reaction (using T4 Ligase) 
Linear Vector (pFastBac with GnT3) 50 ng (1 ul) 
Insert DNA (HBM) 5:1 molar ratio 
10x T4 DNA Ligase Buffer 2 uL 
T4 DNA Ligase 1 uL 
H2O 11 uL 
Total 20 uL 
 
The ligation reaction was incubated at room temperature for 1 hour. After the ligation reaction, 
heat shock transformation was performed using Top10 E.coli cells.  
Although after incubation of the transformed E.coli cells plated on LB-agar with 125mg/mL, 
there were no colonies found on the plate unlike the positive control with a lot of colonies with 
just the pFastBac vector with GnT3.  
Therefore, there must be a possibility that the HBM DNA was lost during the purification 
therefore the digestion, ligation and transformation must be performed again.  
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Sequence of synthesized GnT3 
 
  BamHI                   HBM Tag 
ata GGA TCC ATG aaa ttc tta gtc aac gtt gcc ctt gtt ttt atg gtc 
 EcoRI 
gta tac att tct tac atc tat gcg gat cga GAA TTC cat ttt ttt aaa 
 
acc ctg agc tat gtg acc ttt ccg cgc gaa ctg gcg agc ctg agc ccg 
aac ctg gtg agc agc ttt ttt tgg aac aac gcg ccg gtg acc ccg cag 
gcg agc ccg gaa ccg ggc ggc ccg gat ctg ctg cgc acc ccg ctg tat 
agc cat agc ccg ctg ctg cag ccg ctg ccg ccg agc aaa gcg gcg gaa 
gaa ctg cat cgc gtg gat ctg gtg ctg ccg gaa gat acc acc gaa tat 
ttt gtg cgc acc aaa gcg ggc ggc gtg tgc ttt aaa ccg ggc acc aaa 
atg ctg gaa cgc ccg ccg ccg ggc cgc ccg gaa gaa aaa ccg gaa ggc 
gcg aac ggc agc agc gcg cgc cgc ccg ccg cgc tat ctg ctg agc gcg 
cgc gaa cgc acc ggc ggc cgc ggc gcg cgc cgc aaa tgg gtg gaa tgc 
gtg tgc ctg ccg ggc tgg cat ggc ccg agc tgc ggc gtg ccg acc gtg 
gtg cag tat agc aac ctg ccg acc aaa gaa cgc ctg gtg ccg cgc gaa 
gtg ccg cgc cgc gtg att aac gcg att aac gtg aac cat gaa ttt gat 
ctg ctg gat gtg cgc ttt cat gaa ctg ggc gat gtg gtg gat gcg 
tttgtg gtg tgc gaa agc aac ttt acc gcg tat ggc gaa ccg cgc ccg 
ctg aaa ttt cgc gaa atg ctg acc aac ggc acc ttt gaa tat att cgc 
cat aaa gtg ctg tat gtg ttt ctg gat cat ttt ccg ccg ggc ggc cgc 
cag gat ggc tgg att gcg gat gat tat ctg cgc acc ttt ctg acc cag 
gat ggc gtg agc cgc ctg cgc aac ctg cgc ccg gat gat gtg ttt att 
att gat gat gcg gat gaa att ccg gcg cgc gat ggc gtg ctg ttt ctg 
aaa ctg tat gat ggc tgg acc gaa ccg ttt gcg ttt cat atg cgc aaa 
agc ctg tat ggc ttt ttt tgg aaa cag ccg ggc acc ctg gaa gtg gtg 
agc ggc tgc acc gtg gat atg ctg cag gcg gtg tat ggc ctg gat ggc 
att cgc ctg cgc cgc cgc cag tat tat acc atg ccg aac ttt cgc cag 
tat gaa aac cgc acc ggc cat att ctg gtg cag tgg agc ctg ggc agc 
ccg ctg cat ttt gcg ggc tgg cat tgc agc tgg tgc ttt acc ccg gaa 
ggc att tat ttt aaa ctg gtg agc gcg cag aac ggc gat ttt ccg cgc 
tgg ggc gat tat gaa gat aaa cgc gat ctg aac tat att cgc ggc ctg 
att cgc acc ggc ggc tgg ttt gat ggc acc cag cag gaa tat ccg ccg 
gcg gat ccg agc gaa cat atg tat gcg ccg aaa tat ctg ctg aaa aac 
tat gat cgc ttt cat tat ctg ctg gat aac ccg tat cag gaa ccg cgc 
agc acc gcg gcg ggc ggc tgg cgc cat cgc ggc ccg gaa ggc cgc ccg 
ccg TEV Cleavage Site 
gcg cgc ggc aaa ctg gat gaa gcg gaa gtg aag ggc gaa aac ttg 
tac 
6x His-Tag 
ttt caa ggc cat cac cat cac cat cac TAG 
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Appendix 2: Phosphate Standard curve determined using 1x Assay Buffer. The slope of the 
linear regression line, 1819 pmol/OD, which represents the amount of phosphate corresponding to 
a unit of absorbance at 620 nm. This is referred as the phosphate conversion factor (CF) which 
will be used for subsequent calculations. 
 
